Feeds:
Posts
Comments

Archive for the ‘Conference Coverage with Social Media’ Category

Tweets and Retweets by @AVIVA1950 and by @pharma_BI for 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

Posted in Conference Coverage with Social Media, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Personalized and Precision Medicine & Genomic Research on November 15, 2019| Leave a Comment »

Tweets and Retweets by @AVIVA1950 and by @pharma_BI for 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

Curator: Aviva Lev-Ari, PhD, RN

Tweets and Retweets by @AVIVA1950 and by @pharma_BI for 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

Tweets and Retweets by @AVIVA1950 and by @pharma_BI for 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

see also,

eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

https://pharmaceuticalintelligence.com/2019/07/19/15th-annual-personalized-medicine-conference-at-harvard-medical-school-the-paradigm-evolves-november-13-14-2019-%e2%80%a2-harvard-medical-school-boston-ma/

 

 

Tweets by @AVIVA1950 and by @pharma_BI

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, UPenn’s Perelman School of Medicine no relations explored between Immune T cells and microbiome

2
1

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Impact of Mirobiome it plays a key role in many diseases difficult to develop therapeutics derived from microbiome data

1
1

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Harpreet Singh, Ph.D., CEO, Immatics T Cell peptide started 15 years ago Peptonomics,  tumors of solid cancer – cell therapies selected from libraries  off the shelf cells from health donors Biologics bridges tumor cells and solid cells

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, UPenn’s Medicine CAR-T therapy started the Transfusion Medicine & Therapeutic Biology industry

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Combination therapy emerges, MOA partnerships: cell therapy can transform cancer treatment INFECTIOUS disease had Global impact need stop the virus

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Paul Stoffels, M.D., #CSO

@JandJ

Platforms are established, every 20-30 another one emergences access to data – critical platform AI for diagnostics and decision making biomarkers J&J try to learn on every disease: Lungs and GI Diagnosis HIV Vaccine

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Goals of medicine in 2019 early detection Vaccines in disease prevention Longevity

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Joseph B. Martin, M.D., Ph.D., Dean Emeritus

@HarvardMed

fascinating personal history story on development of interest in genetic analysis

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Michael J. Pellini, MD Diagnostics Pain management  Patients can fight more broadly F for sharing data and data exchange 80% patients do not access Academic Centers for treatment

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Michael J. Pellini, MD surgery, chemo, radiation – cost, harmful, INEFFECTIVE, Dr. Reza Columbia Medical School Oncologist 35 years How are we doing with technology? Very remarkable Clinical Utility to the Payer Regulatory – a super star in ten years

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Stephen L. Eck, Carl June, UPenn Beyond Cancer: Chronic diseases have systemic of specific immune or autoimmune components: CNS, neurodegenerative and Diabetes, Sickle cell anemia – treatment by cell therapy microphages

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Stephen L. Eck, Carl June, UPenn Cost of cell transfection therapy: Cost of Goods, Cost of Labor – pay for performance,  Manufacture in NJ shipped to Europe – not effective

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Stephen L. Eck, Carl June, UPenn Similarity between Transfusion Medicine industry and Cell therapy – Transfection of cells therapy  Manufacturing of Cells for transfection: Over regulation like in small molecules vs too little regulation

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Stephen L. Eck, Carl June, UPenn engineering T cells life farming – innovation is the driver, FDA is evolving in handling patents involved in Cell engineering Regulatory science needs to evolve in light of gene therapy in Human cell line in China

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Stephen L. Eck, Carl June, UPenn Children vs Adults 2011 reported better results in Adults, children’s immune system is evolving  In 2019 – 13 biotech companies in CAR-T cell therapies, Gene therapy is growing FDA, drug cycle T cells vs stem cells

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

15th Annual meeting is at a historic moment in Boston where Prof. Church launched the Human Genome Project and Eric Launder at MIT and the Cancer Genome Project. Genzyme conceived gene therapy sold to Sanofi for $ Billion  Foundation Medicine

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Edward Abrahams, Ph.D., President, PMC 170 drugs with biomarkers, up 15% from 2000 in Biomarker strategy Gene therapy started in 2005, today personalized medicine is becoming standard of care. Science & Technology need additional friendly environment

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Kenna R. Mills Shaw, Ph.D., MD Anderson Institute does not sequence genome of each patient unlike Dana Farber clinicians need to access information for decision making when disease progresses – what new test to order data sharing inside the institute

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, PMC Genomic sequencing for a single test that covers many biomarkers Improve treatment efficiency Growing recognition of the need to demonstrate value, evidence for Payers to pay

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Ammar Qadan, Vice President, Global Head of Market Access, Illumina Illumina is building evidence for Harvard Pilgrim on theirs patient data on risk pregnancies Illumina is expanding  building evidence for ALL rare diseases for all Test diagnostics

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Roy J. Gandolfi, M.D., Medical Director, SelectHealth, UT is the Payer of Intermountain Healthcare, UT Regional approach vs National perspective medical policies requires experts for Payer to approve a treatment Consumer in the health plan

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Lincoln Nadauld, M.D., Ph.D., Chief, Precision Health, Intermountain Healthcare, UT Precision Oncology Program: Need, study, analysis outcome, publish dataPharmacogenetics testing will be covered for all employees & Neonatal

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Peter J. Neumann, Sc.D., Tufts Medical Center clinical utility evidence of value: saving by diagnostics cost for quality cost of diagnostics cost effectiveness – characterize utility cost effectiveness – study Value to families value of knowledge

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Ammar Qadan, Vice President, Global Head of Market Access, Illumina Illumina is partnering with providers and Payer Illumina & Blue Cross Blue Shield 150 Million are covered for genomics 2500 genomics test done Under utilization educate physician

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Mark P. Stevenson, COO Thermo Fisher Scientific Context: Therapy selection in personalized medicine navigate diagnostics in use and policies when implementations is considered Physicians need precise testing now Payers evidence of utility is needed

1

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific Patient Outcome – Data analytics, ML, AI for genomics, proteomics, metabolomics, Tests must be precise and inform the diagnosis by diagnostics Solutions

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Passion of Scientists pharmaceutics development is based on insights looking into the future – important goal to solve

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

best conference on Personalized Medicine in 15 years eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM…
eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA   The 15th Annual …
pharmaceuticalintelligence.com

Aviva Lev-Ari
@AVIVA1950

Your synopsis of the best Personalized Medicine Conference organized to date #PMConf

@pharma_BI
@AVIVA1950
Quote Tweet
Aviva Lev-Ari
@AVIVA1950
·
#PMConf @pharma_BI @AVIVA1950 best conference on Personalized Medicine in 15 years eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA pharmaceuticalintelligence.com/2019/07/19/15t

 Retweet by @AVIVA1950

Aviva Lev-Ari
@AVIVA1950

A true leader in Pharmaceutical domain, also Member of the National Academy of Art and Sciences #PMConf

@pharma_BI
@AVIVA1950
Quote Tweet
Cynthia Bens
@bens_cynthia
·
Introducing the amazing @ScottGottliebMD was a highlight of #pmconf. His vision for balanced regulatory and coverage policies is desperately needed now to support the future of #personalizedmedicine @permedcoalition

Image

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Best Case study

Quote Tweet
PMC
@permedcoalition
·
This year’s #PMConf case study on the @TheDDFund puts a spotlight on what one can do to combine modern entrepreneurial finance approaches to tackle a very complex problem such as Alzheimer’s Disease. @RHamermesh @HarvardHBS #PMConf

Image

Aviva Lev-Ari
@AVIVA1950

#PMConf

@pharma_BI
@AVIVA1950

Edward Abrahams, Ph.D., President, PMC 170 drugs with biomarkers, up 15% from 2000 in Biomarker strategy Gene therapy started in 2005, today personalized medicine is becoming standard of care. Science & Technology need additional friendly environment

1
You Retweeted

Genomic Health®
@GenomicHealth

We’re proud to announce Steve Shak is the recipient of the Leadership in Personalized Medicine Award at the 15th Annual Personalized Medicine Conference: The Paradigm Evolves. Please come and see him speak at the conference. bit.ly/2lMAteZ #PMConf

@permedcoalition

Image

1
7

Read Full Post »

DISCOVER BRIGHAM | NOVEMBER 7, 2019, 10AM – 6PM

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, CAR-T, Conference Coverage with Social Media, Immunotherapy, Scientific & Biotech Conferences: Press Coverage, Transformative Technologies in Healthcare, Translational Science on November 6, 2019| Leave a Comment »

DISCOVER BRIGHAM | NOVEMBER 7, 2019, 10AM – 6PM

Reporter: Aviva Lev-Ari, PhD, RN

 

#DISCOVERBRIGHAM

@pharma_BI

@AVIVA1950

 Aviva Lev-Ari, PhD, RN will be attending and will cover presentations in real time

ABOUT BRIGHAM RESEARCH

Discover Brigham is hosted by the Brigham Research Institute (BRI), under the umbrella of Brigham Health. Launched in 2005, the BRI’s mission is to accelerate discoveries that improve human health by bridging the gaps between science, communication and funding. The BRI’s resources help to foster groundbreaking interdepartmental and interdisciplinary research. They provide a voice for the research community and raise the profile of Brigham Research.

http://www.discoverbrigham.org/.

Speakers

http://www.discoverbrigham.org/speakers/

 

AGENDA

http://www.discoverbrigham.org/agenda/

ASK A QUESTION WITH SLI.DO!

DO YOU WANT TO SUBMIT A QUESTION TO A SPEAKER OF A SESSION? YOU CAN DO IT THROUGH SLI.DO!

1. GO TO THE WEB ADDRESS: SLIDO.COM

2. ENTER THE EVENT CODE: DB19. THEN HIT JOIN!
3. PICK THE SESSION YOU WANT TO ASK A QUESTION. THEN ASK YOUR QUESTION!
4. YOUR QUESTION WILL BE REVIEWED AND MAY BE FORWARDED TO THE CHAIR TO ASK THE SPEAKER(S).

IT WORKS ON ANY DEVICE, YOU DO NOT NEED TO INSTALL ANYTHING!

 

Registration will open at 9:00 AM and will be located throughout the hospital including

  • Schlager Atrium (formerly known as Cabot Atrium, 45 Francis Street Lobby),
  • Schuster Lobby (75 Francis Street Entrance),
  • Shapiro Cardiovascular Center (70 Francis Street Entrance), and the
  • Hale Building for Transformative Medicine (HBTM) 1st Floor (60 Fenwood Road).

 

Click here for directions to these locations.  

NAVIGATING THE BRIGHAM IS EASIER THAN EVER

Need directions to a clinic, conference room, public space, or help assisting someone who looks lost?

Try our browser-based wayfinding tool and mobile app, BWH Maps,
which provides real-time location tracking and directions in the hospital.

Look for BWH Maps on the Apple App Store and Google Play Store,
or visit maps.brighamandwomens.org.

REGISTRATION LOCATIONS

Please visit one of the registration desks listed below to check-in, receive your badge, and collect any necessary materials. Registration will begin starting at 9:00 AM at each of the locations below.

 

Click on each location below for directions. 

  • SCHLAGER ATRIUM, FORMERLY KNOWN AS CABOT ATRIUM (45 FRANCIS ST. LOBBY)
  • SCHUSTER LOBBY (75 FRANCIS ST. LOBBY)
  • CARL J. AND RUTH SHAPIRO
    CARDIOVASCULAR CENTER
  • HALE BUILDING FOR
    TRANSFORMATIVE MEDICINE

SESSION LOCATIONS

Below you will find directions to each of the session locations.

MARSHALL A. WOLF CONFERENCE ROOM

HALE BUILDING FOR TRANSFORMATIVE MEDICINE

SESSION ROOM

FROM 60 FENWOOD ROAD:
Enter at 60 Fenwood Rd lobby entrance.

STAIRS:
Take the lobby staircase to the 2nd floor. Walk past the balcony overlooking the atrium and take the stairs on the left (Stair 2) to the 3rd floor. Once on the 3rd floor, exit the stairwell and take a right. The room is to your right through the double glass door, straight ahead.

ELEVATOR:
Take S Elevator to 3rd floor. Take a right out of the elevator. The room is past the stairwell, on your right through the double glass doors.

HALE VTC 02006B CONFERENCE ROOM

HALE BUILDING FOR TRANSFORMATIVE MEDICINE

OVERFLOW ROOM FOR MARSHALL A. WOLF CONFERENCE ROOM

FROM 60 FENWOOD ROAD:
Enter at 60 Fenwood Rd lobby entrance.

STAIRS:
Take the lobby staircase to the 2nd floor. The conference room will be on your right near the display monitor.

ELEVATOR:
Enter at 60 Fenwood Rd main entrance and take the S Elevator to the 2nd floor. Once you exit the elevator, take a right and walk past the balcony overlooking the atrium and the conference room will be straight ahead near the display monitor.

ZINNER BREAKOUT ROOM

CARL J. AND RUTH SHAPIRO CARDIOVASCULAR CENTER

SESSION ROOM

FROM 70 FRANCIS STREET:
The Zinner Breakout Room is located in the Carl J. and Ruth Shapiro Cardiovascular Center at 70 Francis Street, Boston, MA. Upon entering the building at the street level, walk straight towards the escalators in the rear of the building. The Zinner Conference Center is located on your right; the Breakout room is through the large doors on the left.

ZINNER BOARDROOM

CARL J. AND RUTH SHAPIRO CARDIOVASCULAR CENTER

OVERFLOW ROOM FOR ZINNER BREAKOUT ROOM

FROM 70 FRANCIS STREET:
The Zinner Boardroom is located in the Carl J. and Ruth Shapiro Cardiovascular Center at 70 Francis Street, Boston, MA. Upon entering the building at the street level, walk straight towards the escalator, keeping to the left side of the building. The Conference Center is located on your right; the Boardroom is through the large doors on the back wall.

BORNSTEIN FAMILY AMPHITHEATER

MAIN PIKE, 45 FRANCIS STREET LOBBY

SESSION ROOM

FROM 45 FRANCIS STREET:
Coming from 45 Francis Street lobby, walk towards the Main Pike (2nd floor hallway). Then take left on the Main Pike, 2nd door on right.

AGENDA

10:00 AM – 11:00 AM

Opening remarks

Elizabeth G. Nabel, MD, President Brigham Health, Prof. Medicine @HarvardMed

  • 8th event since 2012
  • show casing amazing research
  • Open to the Public: Patients, Families to educate
  • 90 Posters
  • Health equity perspective as DNA of the Brigham
  • Learn a new idea, meet someone new, create a new idea

Keynote Introduction

David Bates, MD @DBatesSafety

KEYNOTE

INVENTING AND PREDICTING A NEW ERA OF HEALTH WITH AI AND TECHQUITY

KYU RHEE, MD, MPP, VICE PRESIDENT & CHIEF HEALTH OFFICER, IBM CORPORATION & IBM WATSON HEALTH

BORNSTEIN FAMILY AMPHITHEATER

MAIN PIKE, 45 FRANCIS STREET LOBBY
  • Partnership BWH & IBM WATSON
  • Big data of claims from providers to payers
  • Waiting rookms in Healthcare delivery
  • Government: ACA
  • AI Spring is here, no more Winter for AI
  • Health disparities, salaries, sexual orientation – improving health of populations
  • Science & Security
  • Red Hat – data security – big data statoscope
  • Healthcare Culture & Technology Culture: IBM & Amazon hire healthcare professionals
  • Cost: Burnout, managing population health,
  • Reduce physicians burnout
  • Culture Tech – Competition by IBM’s Project Debater

11:15 AM – 12:50 PM

POSTER SESSION

DEMOS

LUNCH

THROUGHOUT THE HOSPITAL

1:00 – 1:50 PM

CLINICAL TRANSLATION OF DISCOVERIES GENERATED IN ENGINEERING IN MEDICINE

ZINNER BREAKOUT ROOM

FROM 70 FRANCIS STREET:
The Zinner Breakout Room is located in the Carl J. and Ruth Shapiro Cardiovascular Center at 70 Francis Street, Boston, MA. Upon entering the building at the street level, walk straight towards the escalators in the rear of the building. The Zinner Conference Center is located on your right; the Breakout room is through the large doors on the left.

Aaron Goldman
HaeLin Jang
Greog K. Gerber
  • Microbiome – Bacteria and Fungus therapies – computational tools for applications on microbiome
  • Diagnostics
  • Microbiome in early childhood
  • temporal variability during adulthood
  • host disease bacteriptherapeutics: C-Diff
  • Bugs as drugs
  • Gnotobiotic mice model for c-Diff in mice
  • MDSINE – Microbial dynamin model interaction model
  • cancer microbiome: Bacteria causing cancer, cancer changing the bacteria environment

 

Jeff Karp BENG PhD @MrJeffKarp

  • tissue based patch to seal open foramane ovale. Project remained in Academic settings however
  • GLUE component was commercialized
  • bioinspiration from living organs in Nature, slugs
  1. Viscose secretions
  2. Hydrophobic secretions and snails and sand castle worms

1:00 – 1:50 PM

CAR T CELLS:
ENGINEERING IMMUNE CELLS TO TREAT CANCER

MARSHALL A. WOLF CONFERENCE ROOM

2:00 – 2:50 PM

HOW INTELLIGENT FAILURE LEADS TO INNOVATION

ZINNER BREAKOUT ROOM

Lina Matta, PharmD
Joji Suzuki, MD
Lisa WIchmann
Kevin Elias, MD
Daiva Braunfelds,MBA HPH
Elizabeth Cullen, MS

2:00 – 2:50 PM

TRANSFORMING MEDICINE THROUGH PREVENTIVE GENOMICS

MARSHALL A. WOLF CONFERENCE ROOM

3:00 – 3:50 PM

HOME HOSPITAL AND THE BRIGHAM EXPERIENCE

ZINNER BREAKOUT ROOM

David Levin
Christopher baugh
Kathryn Britton
Joanne Feinberg Goldstein
Amrita Shahani
If patient meets criteria for Home Hospital : all services are sent home.
2016 – Pilot randomized controlled trial
2017-2018 – Repeat of Pilot on larger population
2018 – High-volume single arm innovation services
2019 – studies within home hospital wtth sensors at home
2020 – continue
Operation and Research lead to innovations

3:00 – 3:50 PM

BLOOD FROM PLANTS

MARSHALL A. WOLF CONFERENCE ROOM

4:00 – 5:00 PM

TURNING “DARK MATTER” OF THE GENOME INTO RNA DRUGS

ZINNER BREAKOUT ROOM

4:00 – 5:00 PM

Anna Krichevsky, PhD HMS Initiative for RNA Medicine

  • paradox of organismal complexity and # protein encoding genes
  • Human genome, 70% Transcriptome Non-coding RNA only 2% encode proteins
  • Non-coding RNA small, long, multifunctional
  • biogenesis of offending RNAs can be drugged
  • RNA novel therapies: RNA as a Drug,
  • Indications: Brain Tumors and AD: MicroRNA (miRNA)the smallest Glioblastoma – only 4 drugs FDA approved in 25 years miRNA – 10b inhibition kills gliomacells miR-132 most neuroprotective RNA
  • Cardiovascular

Paul Anderson, MD, PhD

  • ALS and FTD – Fronto Temporal Dimensia
  • Riluzone 1970 – anti Anti-glutamateric
  • Edarabone 2017 drugs approved – anti-oxidative
  • Andogenesis role in Motor protection from Stress Cytoplasmatic tRNA – ANdiogenin (ANG) production
  • 20 amino acids
  • 5″-tiRNAs assemble G-quadruples – G4
  • point mutationin ANG (mANG) reduce its RNanase
  • G4-containing DNA analogs of 5″-tiRNA (Ala)

Marc Feinberg, MD

  • Cardiovascular: CAD, Insulin resistence – Vascular inflammation
  • Impaired angiogenesis: post MI repair CHF
  • MiRNA therapeutics for Atherosclerosis – miR-181b: Aortic ECs Athero (mice) CAD (Human)
  • miRNA _ Liposomes injected in the vessel wall – reduction of inflammation in vessel – microRNA Group
  • monocyte – How can we increase or amintain mir-181b expression in endothelial cells?
  • LncRNA Therapeutics for vascular Senescence and Atherosclerosis – no effect on leucocyte accumulation no difference in inflammation
  • DNA-dependent protein kinase (DNA-PK)
  • Does Loss SNHG12 triggers vascular senescence in the vessel wall

 

Clemens Scherzer, MD

  • The Protein RNA Brain
  • Dopamin p
  • BRAINCODE: 64% RNA: mRNA, ncRNA,
  • cell-type-spacific putative enhancer RNAs (eRNAs)
  • eRNAs indicate active genetic switches
  • central dogma in Biology: DNA, non-coding RNA, Protein
  • Top 10 Markers
  • Neuropsychiatric Disease: Parkinson: How do genetic variants function in specific brain cells: neurons, microglia, astrocytes
  • genetic variants of neuropsychiatric diseases over-localize to active eRNA sites in dopamine neurons
  • enhancers RNA – ADHD,
  • enhacers RNA – schizoprania, bipolar, addiction – antopsychotic Vlporic acid
  • BRAINCODE Project: BWH MGH HMS

OPIOID AND PAIN INNOVATIONS AT BRIGHAM HEALTH

MARSHALL A. WOLF CONFERENCE ROOM

5:00 – 6:00 PM

AWARDS & RECEPTION

HALE CAFÉ ATRIUM

SPECIAL PHOTO-OP TO CELEBRATE YOU!
WE WILL TAKE A GROUP PHOTO DURING THE RECEPTION AND AWARDS CEREMONY TO CELEBRATE YOU, OUR INNOVATORS!
THE PHOTO WILL BE DISPLAYED AT THE BRIGHAM IN THE HALE BUILDING. WE HOPE YOU CAN JOIN US IN CELEBRATING YOUR ACHIEVEMENTS.

SOURCE

http://www.discoverbrigham.org/agenda/

Read Full Post »

@CHI 1st AI World Conference and Expo, October 23 – October 25, 2019, Seaport World Trade Center, Boston, MA.  Presentations by Four Israeli companies explaining how they use AI technologies in their products @ NEIBC Meetup AI World Conference and Expo, 10/24/2019 @6:30PM Waterfront 1

Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence - General, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Health Care - Tools & Innovations, Conference Coverage with Social Media on October 24, 2019| Leave a Comment »

@CHI 1st AI World Conference and Expo, October 23 – October 25, 2019, Seaport World Trade Center, Boston, MA.  Presentations by Four Israeli companies explaining how they use AI technologies in their products @ NEIBC Meetup AI World Conference and Expo, 10/24/2019 @6:30PM Waterfront 1

#AIWORLD

@AIWORLDEXPO

@pharma_BI

@AVIVA1950

Reporter: Aviva Lev-Ari, PhD, RN

 

  • When: October 24, 2019
  • Time: 6:30 pm
  • Where: Seaport World Trade Center, Boston, MA
  • Room Location: Waterfront 1

Speakers Includes:

Registration:

  • To gain access to NEIBC Meetup please RSVP below and use code 1968-EXHP and get complimentary pass to the exhibit
  • If you want to attend the conference, use NEIBC19 discount code and get $200 off conference registration

RSVP NOW

AI World Conference and Expo has become the industry’s largest independent business event focused on the state of the practice of AI in the enterprise. The AI World 3-day program delivers a comprehensive spectrum of content, networking, and business development opportunities, all designed to help you cut through the hype and navigate through the complex landscape of AI business solutions. Attend AI World and learn how innovators are successfully deploying AI and intelligent automation to accelerate innovation efforts, build competitive advantage, drive new business opportunities, and reduce costs.

250+ Speakers

120+ Sponsors

2700+Attendees

100+Sessions

SOURCE

From: “Dan Trajman @ NEIBC” <dan.trajman@neibc.org>

Reply-To: <dan.trajman@neibc.org>

Date: Wednesday, October 23, 2019 at 11:50 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Israeli Companies Presenting at AI World October 24, 2019

 

Event Brochure

https://aiworld.com/docs/librariesprovider28/agenda/19/aiworld-conference-expo-2019.pdf

 

Plenary Program

WEDNESDAY, OCTOBER 23

9:00 AM SUMMIT KICK OFF: AI Becomes Real

Scott Lundstrom, Group Vice President and General Manager, IDC

Government and Health Insights, IDC and AI World, Conference Co-Chair

 

9:10 AM SUMMIT KEYNOTE: Business Strategy with Artificial Intelligence

Sam Ransbotham, PhD, Professor, Academic Contributing Editor,

Information Systems, Boston College; MIT Sloan Management Review

 

9:35 AM EXECUTIVE ROUNDTABLE:

AI Drives Innovation in Enterprise Applications

Moderator: Mickey North-Rizza, Research Vice President, Enterprise Applications, IDC

Panelists:

David Castillo, PhD, Managing Vice President, Machine Learning, Capital One

Mukesh Dalal, PhD, Chief Analytics Officer & Chief Data Scientist, Bose Corporation

Madhumita Bhattacharyya, Managing Director – Enterprise Data & Analytics,

Protiviti Sasha Caskey, CTO & Co-Founder, Kasisto

 

10:05 AM KEYNOTE: Evolving Role of CDAOS in the New Era – An Organizational Construct

Anju Gupta, Vice President, Chief Data and Analytics Officer, Enterprise Holdings

 

10:30 – 10:50 AM NETWORKING BREAK

 

10:50 AM EXECUTIVE ROUNDTABLE:

 

The Evolution of Conversational Assistants

 

Moderator:

Reenita Malholtra Hora, Director of Marketing & Communications, SRI International

Panelists:

William Mark, PhD, President, SRI

Karen Myers, Lab Director, SRI International’s AI Center

 

11:20 AM Talk Title to be Announced

Genevy Dimitrion VP, Enterprise Data and Analytics, Humana

 

11:40 AM How AI Maturity Impacts a Winning Corporate Strategy

Ritu Jyoti, Program Vice President, IDC

 

4:20 PM PLENARY KEYNOTE PANEL:

Learning from XPRIZE Startups to Achieve Successful AI Innovation

Moderator:

Devin Krotman, Director, IBM Watson

AI XPRIZE,

XPRIZE Foundation

 

Panelists: Eleni Miltsakaki, Founder and CEO, Choosito

Ellie Gordon, Founder, CEO, & Designer, Behaivior AI

Daniel Fortin, President, AITera Inc.

 

12:00 PM LUNCHEON KEYNOTE:

Case Studies of Conversational AI – Real Deployments at Scale

Jim Freeze, Chief Marketing Officer, Interactions

 

Sponsored by Ben Bauks, Senior Business Systems Analyst, Constant Contact

 

THURSDAY, OCTOBER 24

 

8:20 AM BREAKFAST KEYNOTE:

The Promise and Pain of Computer Vision in Retail, Healthcare, and Agriculture

Ben Schneider, Vice President, Product, Alegion

 

9:00 AM CONFERENCE INTRODUCTION

Eliot Weinman, Founder & Conference Chair, AI World; Executive Editor, AI Trends

 

9:05 AM INTRODUCTORY REMARKS

Scott Lundstrom, Group Vice President and General Manager, IDC Government and

Health Insights, IDC and AI World, Conference Co-Chair

 

9:15 AM KEYNOTE PRESENTATION:

The Human Strategy

Alex Sandy Pentland, PhD, Professor, Engineering, Business, Media Lab, MIT

 

9:45 AM KEYNOTE:

Uber’s Intelligent Insights Assistant

Franziska Bell, PhD, Director, Data Science, Data Science Platforms, Uber

 

10:15 AM KEYNOTE:

AI in Finance: Present and Future, Hype and Reality

Charles Elkan, PhD, Managing Director, Goldman Sachs

 

10:40 – 11:00 AM COFFEE BREAK

 

11:00 AM KEYNOTE:

AI at Work in Legal, News and Tax & Accounting

Khalid Al-Kofahi, PhD, Vice President, Research and Development, Head –

Center for AI and Cognitive Computing, Thomson Reuters

 

11:25AM EXECUTIVE ROUNDTABLE:

Disinformation, Infosec, Cognitive Security and Influence Manipulation

Moderator:

Michael Krigsman, Industry Analyst, CXOTalk

 

Panelist:

Sara-Jayne Terp, Data Scientist, Bodacea Light Industries LLC

Bob Gourley, Co-Founder and CTO, OODA LLC

Pablo Breuer, Director of US Special Operations Command Donovan Group and Senior Military Advisor and Innovation Officer, SOFWERX

Anthony Scriffignano, PhD, SVP, Chief Data Scientist, Dun & Bradstreet

 

Sponsored by

PUSHING THE BOUNDARIES OF AI – Providing the expertise required to accelerate the evolution of human progress in the age of artificial intelligence http://dellemc.com/AI

 

11:30 AM KEYNOTE:

How AI is Helping to Improve Canadian Lives Through AML

Vishal Gossain, Vice President, Global Risk Management, ScotiaBank

 

FRIDAY, OCTOBER 25

 

8:15 AM KEYNOTE:

AI World Society Roundtable on AI-Healthcare

Moderator:

Ed Burns, Site Editor, TechTarget

 

Panelists:

Professor David Silbersweig, Board Member of BGF, Harvard Medical

School

Professor Mai Trong Khoa, PhD, Chairman of the Nuclear Medicine and Oncology

Council, Director of the Gene-Stem cell Center, Bach Mai hospital, Senior lecturer,

Hanoi Medical University, Secrectary of the National Council of Professorship in

Medicine in Vietnam

Truong Van Phuoc, PhD, Former Acting Chairman, State Inspectory Committee

of Finance of Vietnam, Senior Advisor to Chairman, Vietbank

Truong Vinh Long, MD, CEO, Gia An 115 Hospital

 

10:00 AM KEYNOTE:

AI in Pharma: Where we are Today and How we Will Succeed in the Future

Natalija Jovanovic, PhD, Chief Digital Officer, Sanofi Pasteur

 

10:30 AM Startup Awards Announcement

John Desmond, Principal at JD Content Services, Editor AI Trends

 

10:35 – 10:50 AM COFFEE BREAK IN THE EXPO

 

10:50 AM EXECUTIVE ROUNDTABLE:

Enterprise AI Innovations

Moderator:

Nick Patience, Founder & Research Vice President, Software, 451 Research

Rudina Seseri, Founder and Managing Partner, Glasswing Venture

Norbert Monfort, Vice President, IT Transformation and Innovation, Assurant Global Technology

Dawn Fitzgerald, Director of Digital Transformation Data Center Operations, Schneider Electric

 

PLENARY PROGRAM

 

8:45 AM CONFERENCE INTRODUCTION

Scott Lundstrom, Group Vice President and General Manager, IDC Government and

Health Insights, IDC and AI World, Conference Co-Chair

 

8:50 AM KEYNOTE:

Artificial Intelligence in Sustainable Development: An Educational Perspective

Enver Yucel, Chairman, Bahçeşehir University

 

9:00 AM KEYNOTE:

Enhancing Human Capability with Intelligent Machine Teammates

Julie Shah, Associate Professor, Dept of Aeronautics and Astronautics, Computer Science and AI Lab, MIT

 

9:30 AM KEYNOTE:

Democracy, Ethics and the Rule of Law in the Age of Artificial Intelligence

Paul F. Nemitz, Principal Advisor in the Directorate-General for Justice and Consumers of the European Commission

 

12:00 PM LUNCHEON KEYNOTE:

How AI/ML is Changing the Face of Enterprise IT

Robert Ames, Senior Director, National Technology Strategy,

VMware Research, VMware

 

SOURCE

https://aiworld.com/docs/librariesprovider28/agenda/19/aiworld-conference-expo-2019.pdf

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: Dealmakers’ Intentions: 2019 Market Outlook June 5 Philadelphia PA

Posted in Conference Coverage with Social Media, tagged , , , , on October 15, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: Dealmakers’ Intentions: 2019 Market Outlook June 5 Philadelphia PA

Reporter: Stephen J Williams, PhD @StephenJWillia2

Speakers

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

 

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: Can Genome Editing Fulfill Its Promise and Meet Unmet Medical Needs? Philadelphia PA

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Conference Coverage with Social Media, CRISPR applied to Human Germ Line, CRISPR/Cas9 & Gene Editing, Disease Biology, Gene Editing Impact on Longevity, Gene Therapy & Gene Editing Development, Genetics & Innovations in Treatment, Genome Biology, tagged , , , , , , , , on October 15, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: Can Genome Editing Fulfill Its Promise and Meet Unmet Medical Needs? Philadelphia PA

Reporter: Stephen J. Williams, PhD

 

118A, Level 100

Speakers
Human gene editing continues to hold a major fascination within a biomedical and biopharmaceutical industries. It’s extraordinary potential is now being realized but important questions as to who will be the beneficiaries of such breakthrough technologies remained to be answered. The session will discuss whether gene editing technologies can alleviate some of the most challenging unmet medical needs. We will discuss how research advances often never reach minority communities and how diverse patient populations will gain access to such breakthrough technologies. It is widely recognize that there are patient voids in the population and we will explore how community health centers might fill this void to ensure that state-of-the-art technologies can reach the forgotten patient groups . We also will touch ethical questions surrounding germline editing and how such research and development could impact the community at large.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers], 2019 – 2020 

Posted in Conference Coverage with Social Media, LPBI Group Founder - Aviva Lev-Ari, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on August 6, 2019| Leave a Comment »

For @AVIVA1950, Founder, LPBI Group @pharma_BI:

Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies]

&

Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers], 2019 – 2020

 

Data collection from Twitter Analytics on @AVIVA1950: Aviva Lev-Ari, PhD, RN

https://analytics.twitter.com/user/AVIVA1950/tweets

SEE DEFINITIONS, below

 

Twitter Summary for @AVIVA1950, 1/2019 – 4/2020

The Spikes in Profile visits, in Number of Tweets and in Number of Mentions are related to REAL TIME Press Coverage of Leading Conferences.

  • On 3/14/2020 we launched the Coronavirus Portal and promoted it on Twitter.com

List of Conferences covered in 2019 by @AVIVA1950

 

  • Koch Institute 2019 Immune Engineering Symposium, January 28-29, 2019, Kresge Auditorium, MIT

https://calendar.mit.edu/event/immune_engineering_symposium_2019#.XBrIDc9Kgcg

http://kochinstituteevents.cvent.com/events/koch-institute-2019-immune-engineering-symposium/event-summary-8d2098bb601a4654991060d59e92d7fe.aspx?dvce=1

 

  • 2019 MassBio’s Annual Meeting, State of Possible Conference ​, March 27 – 28, 2019, Royal Sonesta, Cambridge

http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf

 

  • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON

https://worldmedicalinnovation.org/agenda-list/

https://worldmedicalinnovation.org/

 

  • 18th Annual 2019 BioIT, Conference & Expo, April 16-18, 2019, Boston, Seaport World Trade Center, Track 5 Next-Gen Sequencing Informatics – Advances in Large-Scale Computing

http://www.giiconference.com/chi653337/

https://pharmaceuticalintelligence.com/2019/04/22/18th-annual-2019-bioit-conference-expo-april-16-18-2019-boston-seaport-world-trade-center-track-5-next-gen-sequencing-informatics-advances-in-large-scale-computing/

 

  • Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

https://pharmaceuticalintelligence.com/2019/04/25/translating-genetics-into-medicine-april-25-2019-830-am-600-pm-the-new-york-academy-of-sciences-7-world-trade-center-250-greenwich-st-fl-40-new-york/

 

  • 13th Annual US-India BioPharma & Healthcare Summit, May 9, 2019, Marriott, Cambridge

https://pharmaceuticalintelligence.com/2019/04/30/13th-annual-biopharma-healthcare-summit-thursday-may-9-2019/

 

  • 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, May 17, 2019, Harvard Law School

http://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference

https://pharmaceuticalintelligence.com/2019/01/11/2019-petrie-flom-center-annual-conference-consuming-genetics-ethical-and-legal-considerations-of-new-technologies/

 

  • Not included in this data: Real Time Coverage of BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center; Philadelphia PA by Stephen J. Williams, PhD @StephenJWillia2

Reporter: Stephen J. Williams, PhD @StephenJWillia2

https://pharmaceuticalintelligence.com/2019/05/31/real-time-coverage-of-bio-international-convention-june-3-6-2019-philadelphia-convention-center-philadelphia-pa/

 

  • 2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM  ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA

https://pharmaceuticalintelligence.com/2019/03/12/2019-koch-institute-symposium-machine-learning-and-cancer-june-14-2019-800-am-500-pmet-mit-kresge-auditorium-48-massachusetts-ave-cambridge-ma/

 

 

 

  • 2019 Warren Alpert Foundation Award Ceremony and Acceptance Lectures by Awardees, October 3, 2019, Harvard Medical School, Boston, MA Award goes to Four Scientists for Seminal Discoveries in OptoGenetics – Illuminating the Human Brain

https://pharmaceuticalintelligence.com/2019/07/18/2019-warren-alpert-foundation-award-goes-to-four-scientists-for-seminal-discoveries-in-optogenetics-illuminating-the-human-brain/

 

 

  • 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

https://pharmaceuticalintelligence.com/2019/07/19/15th-annual-personalized-medicine-conference-at-harvard-medical-school-the-paradigm-evolves-november-13-14-2019-%e2%80%a2-harvard-medical-school-boston-ma/

 

https://pharmaceuticalintelligence.com/2019/07/23/2019-new-england-venture-summit-december-4th-2019-at-the-hilton-in-boston-dedham-ma-hosted-by-youngstartup-nevs/

 

Twitter Summary for @AVIVA1950, 1/1/2019 – 4/20/2020

Month Tweets Profile visits Mentions Followers Tweet impressions
Jan-19 21 25,100
Feb-19 1 62 21 23,100
Mar-19 155 533 153 10 23,500
Apr-19 257 690 235 14 64,200
May-19 281 691 238 28 70,400
Jun-19 206 581 170 23 58,400
Jul-19 83 321 62 15 25,500
Aug-19 121 218 86 10 27,700
Sep-19 59 97 36 -6 28,400
Oct-19 67 50 36 6 23,600
Nov-19 175 165 157 8 53,300
Dec-19 116 128 81 8 32,000
Jan-20 50 66 40 5 12,500
Feb-20 53 122 42 11 17,600
Mar-20 146 96 129 6 27,300
Apr-20 264 282 132 3 28,300

 

Twitter Summary for @AVIVA1950, 5/1/2020 – 12/31/2020

Month

 Tweets

 

 Tweet impressions

 

 Profile visits

 

 Mentions

 

 Followers

 
Dec20          
Nov20          
Oct20          
Sept20          
Aug20          
July20          
June20          
May20          

March 2020 & April 2020

Coronavirus Portal was Launched on 3/14/2020 to May 8, 2020

  • Your Tweets earned 53.7K impressions over this 56 day period
  • Your Tweets earned 952 impressions per day over this 56 day period

Top Engagement Rate (%)

Aviva Lev-Ari @AVIVA1950  Apr 284-28-2020 UPDATES on of -measures for #2019-nCoV, , via
9
1
11.1%

Top Impressions

TWEET HIGHLIGHTS – April 2020

Top Tweet earned 357 impressions

I agree strategy: Serology kits for IgG and IgM need be made available and accessible for self administration. IF positive on IgG call in and IF positive on IgM do not call in. IF negative on IgG THEN negative on IgM. Follow @
View all Tweet activityView Tweet activity
Impressions
366

Top Follower followed by 144K people

@DoctorPete FOLLOWS YOU

     ™    Author https://t.co/3zMGR2Mdpi   

View profile

Top mention earned 12 engagements

I agree strategy: Serology kits for IgG and IgM need be made available and accessible for self administration. IF positive on IgG call in and IF positive on IgM do not call in. IF negative on IgG THEN negative on IgM. Follow @
View all Tweet activity

TWEET HIGHLIGHTS – March 2020

Top Tweet earned 1,367 impressions

Task Force: COVID-19 Testing Site Expansion Set website CRITICAL information shared
 2
View all Tweet activityView Tweet activity

Top Follower followed by 113K people

@ipfconline1 FOLLOWS YOU

Digital Transformation Consulting        

View profile

January to July 2019

Impressions, Engagement Rate, Link Clicks, Retweets, Likes, Replies

 

2019

Average Impressions per day by Month

 Monthly

Average

Engagement Rate

&

Last day of the month

 Monthly

Average

Link Clicks

& Last day of the month

& average link clicks per day

 Monthly

Average Retweets

& Last day of the month

& average Retweets per day

 Monthly

Average

Likes

& Last day of the month

& average Likes per day

Monthly

Average Replies

& Last day of the month

& average Replies per day

January 31

N = 809

 2.4% / 2.2% 33 / 3 / 1 80 / 4 / 3 129 / 5 / 4

2 /1 /0

February 28

N = 825

 2.1% / 11.7% 22 / 0 / 1 24 / 3 / 1 41 / 1 / 1

1 / 0 / 0

March 31

N = 759

 2.5% / 0.5% 18 / 1/ 1 37 / 1/ 1 63 / 1 / 2 1 / 0 / 0

April 30

N = 2.1K

 1.0% / 1.8% 21 / 1/ 1 130 / 3 / 4 201 / 3 / 7

0 / 0/ 0

May 31

N = 2.3K

 1.3% / 1.2% 51 / 3 / 2 117 / 2 / 4 142 / 2 / 5

3 / 0 / 0

June 30

N = 1.9K

 1.2% / 0.1% 33 / 0 / 1 124 / 1 / 4 161 / 0 / 5

1 / 0 / 0

July 31

N = 824

 0.9% / 1.1% 54 / 4/ 2 42 / 6 / 1 40 / 3 / 1

3 / 0 / 0

August

N =

October

N =

November

N =

December

N =

Tweets, Impressions, Profile Visits, Mentions, New Followers

2019

 Tweets Impressions Profile visits Mentions New Followers

January

25.1K 21

February

 1 23.1K 62

21
March 155 23.5K 533 153

10

April

 257 64.2K 690 235 14

May

 281 70.4K 691 238

28
June

206

 58.4K 581 170

23

July

 83 25.5K 321 62

15

August

 121 27.7K 218 86 10

September

 59 28.4K 97 36 -6

October

 67 23.6K 50 36 6

November

 175 53.3K 165 157 8

December

 116 32K 128 81 8

Jul 2019 • 31 days

TWEET HIGHLIGHTS

Top Tweet earned 1,681 impressions

Endorsed by , Editors NEW
 2  3
View all Tweet activityView Tweet activity

Top Follower followed by 112K people

Cox Business

@coxbusiness FOLLOWS YOU

Leading provider of Internet, phone & tv services for   &  Grow your  – Visit https://t.co/gmfFBMeTIA & https://t.co/f64tLDZpwN

View followers dashboardView profile

Top mention earned 36 engagements

Endorsed by , Editors NEW
 2  3
View all Tweet activity
JUL 2019 SUMMARY

Tweets

83

Tweet impressions

25.5K

Profile visits

321

Mentions

62

New followers

15

Jun 2019 • 30 days

TWEET HIGHLIGHTS

Top Tweet earned 2,280 impressions

as and are in unidirectional symbiosis Food affect Microbiome in turn it affects of individuals over theirs
 5  4
View all Tweet activityView Tweet activity

Top Follower followed by 289K people

@tveitdal FOLLOWS YOU

Tweeting Climate Change news. Climate lecturer: science, policy, solutions. Director Klima 2020, former UN Director. For contact use svein@klima2020.no

View followers dashboardView profile

Top mention earned 21 engagements

eProceeding 2019 Koch Institute Symposium – 18th Annual Cancer Research Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PMET MIT Kresge Auditorium, Cambridge, MA via
 1  1
View all Tweet activityView Tweet activity
JUN 2019 SUMMARY

Tweets

206

Tweet impressions

58.4K

Profile visits

581

Mentions

170

New followers

23

May 2019 • 31 days

TWEET HIGHLIGHTS

Top Tweet earned 3,800 impressions

create application for robots, we picked pruned by hand in high school as Summer job.
 6  5
View all Tweet activityView Tweet activity

Top Follower followed by 202K people

Alexander Verbeek 🌍

@Alex_Verbeek FOLLOWS YOU

Public Speaker | Moderator | Diplomat | Photographer | Yale World Fellow | Climate Change | Wildlife | Environment | Art | Energy-Water-Food | Sustainability 🌱

View followers dashboardView profile

Top mention earned 36 engagements

Next Generation targeted three chemical elements Gd Fe Mn
 6  10
View all Tweet activityView Tweet activity

Top media Tweet earned 1,319 impressions

Dr. Maus ⁩ monitoring data from clinical trial is very important development of new targets multiple drugs multiple mechanism multiple specificities more modification to one cell contamination results
 3  3
View all Tweet activityView Tweet activity
MAY 2019 SUMMARY

Tweets

281

Tweet impressions

70.4K

Profile visits

691

Mentions

238

New followers

28

Apr 2019 • 30 days

TWEET HIGHLIGHTS

Top Tweet earned 2,758 impressions

The premise of applied to 30 babies in 1st week of life new to intervention to cause desirable # molecular changes by search immunology search
 7  12
View all Tweet activityView Tweet activity

Top Follower followed by 253K people

@evankirstel FOLLOWS YOU

    helping clients w/  in     

View followers dashboardView profile

Top mention earned 56 engagements

Marc Smith@marc_smith  Apr 9 via NodeXL Top hashtags:
 9  9
View Tweet

Top media Tweet earned 1,652 impressions

Amazing Disruptive Dozen Technologies ⁦⁩ ⁦⁩ Third Annette Kim streamlining Diagnosis Second Thomas McCoy prediction of Suicide risk FIRST Alexandra Golby Neurosurgery Imaging AI based system real time dynamic data intraop
 1  1
View all Tweet activityView Tweet activity
APR 2019 SUMMARY

Tweets

257

Tweet impressions

64.2K

Profile visits

690

Mentions

235

New followers

14

Mar 2019 • 31 days

TWEET HIGHLIGHTS

Top Tweet earned 624 impressions

⁦⁩ ⁦⁩ ⁦⁩ @BEAM as a faulty ONE LETTER AT A TIME
 1
View all Tweet activityView Tweet activity

Top Follower followed by 450K people

@CMichaelGibson FOLLOWS YOU

Non-Profit Founder/Leader | ❤️ Doc | Artist | Scientist | Educator | Med News Anchor https://t.co/LDrNxgwhA4 | RT ≠ endorse | Disclaimer here: https://t.co/2jtJQZQU0H

View followers dashboardView profile

Top mention earned 8 engagements

⁦⁩ impact of , how to maintain Boston as Biotech HUB? with ⁦⁩ attract great talent ⁦⁦⁩ culture is asset on the balance sheet PARKING
 1  2
View all Tweet activityView Tweet activity

Top media Tweet earned 440 impressions

⁦⁩ in 2018 greater than in the US active in the &
 2
View all Tweet activityView Tweet activity
MAR 2019 SUMMARY

Tweets

155

Tweet impressions

23.5K

Profile visits

533

Mentions

153

New followers

10

Feb 2019 • 28 days

TWEET HIGHLIGHTS

Top Tweet earned 795 impressions

: teams with , on $50M initiative
 1  2
View all Tweet activityView Tweet activity

Top Follower followed by 252K people

@ArtistsandMusic FOLLOWS YOU

Music Lovers Network . ♫♫ Connecting  talented  with , A&Rs and Fans.   

View followers dashboardView profile

Top mention earned 6 engagements

Great review
 4  2
View all Tweet activityView Tweet activity

Top media Tweet earned 55 impressions

My week on Twitter 🎉: 34 Mentions, 10.6K Mention Reach, 18 Likes, 7 Retweets, 6.7K Retweet Reach. See yours with
 1
View all Tweet activityView Tweet activity
FEB 2019 SUMMARY

Tweets

1

Tweet impressions

23.1K

Profile visits

62

New followers

21

Jan 2019 •31 days

TWEET HIGHLIGHTS

Top Follower followed by 450K people

@CMichaelGibson FOLLOWS YOU

Non-Profit Founder/Leader | ❤️ Doc | Artist | Scientist | Educator | Med News Anchor https://t.co/LDrNxgwhA4 | RT ≠ endorse | Disclaimer here: https://t.co/2jtJQZQU0H

View followers dashboardView profile
JAN 2019 SUMMARY

Tweet impressions

25.1K

New followers

21

Definitions

An engagement rate between 0.09% and 0.33% is considered to be high, where an influencer would expect 0.9 – 3.3 reactions for every 1000 followers onTwitter. Finally, an engagement rate between 0.33% and 1% is considered to be very high, with expected reactions to be between 3.3 – 10 for every 1000 Twitter followers.

What is a Good Engagement Rate on Twitter? – Scrunch

https://www.scrunch.com/blog/what-is-a-good-engagement-rate-on-twitter

How to calculate engagement rate on Twitter?

The Tweet Engagement Rate Formula.
The Tweet Engagement Rate takes into account the Replies and Retweets of the Tweet to the total number of Followers to date. Then it´s multiplied by 100 as well to provide you with the percentage of your Fan base that´s interacting with your Tweet.

Formulas Revealed: The Facebook and Twitter Engagement Rate …

https://www.socialbakers.com/…/467-formulas-revealed-the-facebook-and-twitter-engag&#8230;

6 engagement rate calculation methods

These are the most common formulas you’ll need to calculate engagement rates on social media.

Total engagements typically represents a tally of likes, favourites, reactions, comments, shares, views, retweets, and sometimes include clicks, depending on which platform you’re using.

1. Engagement rate by reach (ERR)

This formula is the most common way to calculate engagement with content.

ERR measures the percentage of people who chose to interact with your content after seeing it.

Use the first formula for a single post, and the second one to calculate the average rate across multiple posts.

  • ERR = total engagements per post / reach per post * 100

To determine the average, add up the all the ERRs from the posts you want to average, and divide by number of posts:

  • Average ERR = Total ERR / Total posts

In other words: Post 1 (3.4%) + Post 2 (3.5%) / 2 = 3.45%

Pros: Reach can be a more accurate measurement than follower count, since not all your followers will see all your content. And non-followers may have been exposed to your posts through shares, hashtags, and other means.

Cons: Reach can fluctuate for a variety of reasons, making it a different variable to control. A very low reach can lead to a disproportionately high engagement rate, and vice versa, so be sure to keep this in mind.

2. Engagement rate by posts (ER post)

Technically, this formula measures engagements by followers on a specific post. In other words, it’s similar to ERR, except instead of reach it tells you the rate at which followers engage with your content.

Most social media influencers calculate their average engagement rate this way.

  • ER post = Total engagements on a post / Total followers *100

To calculate the average, add up all the ER posts you want to average, and divide by number of posts:

  • Average ER by post = Total ER by post / Total posts

Example: Post 1 (4.0%) + Post 2 (3.0%) / 2 = 3.5%

Pros: While ERR is a better way to gauge interactions based on how many people have seen your post, this formula replaces reach with followers, which is generally a more stable metric.

In other words, if your reach fluctuates often, use this method for a more accurate measure of post-by-post engagement.

Cons: As mentioned, while this may be a more unwavering way to track engagements on posts, it doesn’t necessarily provide the full picture since it doesn’t account for viral reach. And, as your follower count goes up, your rate of engagement could drop off a little.

Make sure to view this stat alongside follower growth analytics.

Bonus: Get a free social media report template to easily and effectively present your social media performance to key stakeholders.

Get the free template now!

3. Engagement rate by impressions (ER impressions)

Another base audience metric you could choose to measure engagements by is impressions. While reach measures how many people see your content, impressions tracks how often that content appears on a screen.

  • ER impressions = Total engagements on a post / Total impressions *100
  • Average ER impressions = Total ER impressions / Total posts

Pros: This formula can be useful if you’re running paid content and need to evaluate effectiveness based on impressions.

Cons: An engagement rate calculated with impressions as the base is bound to be lower than ERR and ER post equations. Like reach, impression figures can also be inconsistent. It may be a good idea to use this method in conjunction with reach.

Read more about the difference between reach and impressions.

4. Daily engagement rate (Daily ER)

While engagement rate by reach measures engagement against maximum exposure, it’s still good to have a sense of how often your followers are engaging with your account on a daily basis.

  • Daily ER = Total engagements in a day / Total followers *100
  • Average Daily ER = Total engagements for X days / (X days *followers) *100

Pros: This formula is a good way to gauge how often your followers interact with your account on a daily basis, rather than how they interact with a specific post. As a result, it takes engagements on new and old posts into equation.

This formula can also be tailored for specific use cases. For instance, if your brand only wants to measure daily comments, you can adjust “total engagements” accordingly.

Cons: There’s a fair amount of room for error with this method. For instance, the formula doesn’t account for the fact that the same follower may engage 10 times in a day, versus 10 followers engaging once.

Daily engagements can also vary for a number of reasons, including how many posts you share. For that reason it may be worthwhile to plot daily engagement versus number of posts.

5. Engagement rate by views (ER views)

If video is a primary vertical for your brand, you’ll likely want to know how many people choose to engage with your videos after watching them.

  • ER view = Total engagements on video post / Total video views *100
  • Average ER view = Total ER view / Total posts

Pros: If one of your video’s objectives is to generate engagement, this can be a good way to track it.

Cons: View tallies often include repeat views from a single user (non-unique views). While that viewer may watch the video multiple times, they may not necessarily engage multiple times.

6. Factored Engagement Rate

In rare cases some marketers use a “factored engagement rate.” As the name suggests, factored engagement rates add more or less weight to certain factors in the equation.

For example, a marketer may wish to place a higher value on comments versus likes, weighting each comment as two versus one. The subsequent equation would look something like this:

  • Comment-weighted ER = (Total comments x 2) + all other engagements / Reach per post *100

Obviously, this technique inflates the resulting engagement rate and can be misleading, especially since the use of factored engagement rates is not widespread. For this reason, Hootsuite does not recommend its use.

SOURCE

https://blog.hootsuite.com/calculate-engagement-rate/

How To Measure An Influencer’s Engagement Rate (A Scientific …

 

https://www.scrunch.com/blog/measuring-an-influencers-engagement-rate

 

Read Full Post »

MinneBOS 2019 Field Guide to Data Science & Emerging Tech in the Boston Community, August 22, 2019 8AM to 5PM at Boston University Questrom School of Business, 595 Commonwealth Avenue, Boston, MA

Posted in Big Data, BioIT: BioInformatics, Conference Coverage with Social Media, Intelligent Information Systems on July 31, 2019| Leave a Comment »

MinneBOS 2019, Field Guide to Data Science & Emerging Tech in the Boston Community

August 22, 2019, 8AM to 5PM at Boston University Questrom School of Business, 595 Commonwealth Avenue, Boston, MA

 

 

MinneBOS – Boston’s Field Guide to Data Science & Emerging Tech

Announcement

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

REAL TIME Press Coverage for

 http://pharmaceuticalintelligence.com 

by

 Aviva Lev-Ari, PhD, RN

Director & Founder, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief, Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com

Editor-in-Chief, BioMed e-Series, 16 Volumes in Medicine, https://pharmaceuticalintelligence.com/biomed-e-books/

@pharma_BI

@AVIVA1950

#MinneBos

 

Logo, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Our BioMed e-series

WE ARE ON AMAZON.COM

 

https://lnkd.in/ekWGNqA

 

UPDATED AGENDA

Thursday, August 22 • 9:30am – 10:15am
Advancing Cancer Research with Deep Learning Image Analysis
Histopathological images are the gold standard tool for cancer diagnosis, whose interpretation requires manual inspection by expert pathologists. This process is time-consuming for the patients and subject to human error. Recent advances in deep learning models, particularly convolutional neural networks, combined with big databases of patient histopathology images will pave the path for cancer researchers to create more accurate guiding tools for pathologists. In this talk, I will review the latest advances of big data in healthcare analytics and focus on deep learning applications in cancer research. Targeted at a general audience, I will provide a high-level overview of technical concepts in deep learning image analysis, and describe a typical cloud-based workflow for tackling such big data problems. I will conclude my talk by sharing some of our most recent results based on a wide range of cancer types.

Speakers

avatar for Mohammad Soltanieh-ha, PhD

Mohammad Soltanieh-ha, PhD

Clinical Assistant Professor, Boston University – Questrom
Mohammad is a faculty at Boston University, Questrom School of Business, where he teaches data analytics and big data to master’s students. Mohammad’s current research area involves deep learning and its applications in cancer research.

10:15am

Break

10:30am

Thursday, August 22 • 10:30am – 11:00am

Deep learning image recognition and classification models for fashion items

Large scale image recognition and classification is an interesting and challenging problem. This case study uses fashion-MNIST dataset that involves 60000 training images and 10000 testing images. Several popular deep learning models are explored in this study to arrive at a suitable model with high accuracy. Although convolutional neural networks have emerged as a gold-standard for image recognition and classification problems due to speed and accuracy advantages, arriving at an optimal model and making several choices at the time of specifying model architecture, is still a challenging task. This case study provides the best practices and interesting insights.

Speakers

avatar for Bharatendra Rai

Bharatendra Rai

Professor, UMass Dartmouth
Bharatendra Rai, Ph.D. is Professor of Business Analytics in the Charlton College of Business at UMass Dartmouth. His research interests include machine learning & deep learning applications.
  • Train data: 60,000
  • Test data: 10,000
  • Dataset available from Google MNIST Fashion Data – items in DB: data already labelled
  • Label and Description
  • Architecture: Input >> Conv >> Conv >> Pooling >> Dropout << Dense <<Flatten << Dropout >> Output
  • CNN vs Fully connected: 320 parameters: 3x3x1x32 + [32 BIAS TERM] = 320 vs
  • fully connected network parameters is 16 million
  • Train the model: 15 iterations – Training and Validation
  • Actual vs Predicted: 94% was classified correctly = Accuracy: 94% 5974 vs 4700 (78%)
  • Confusion Matrix – Test 720 correctly classified for item 6  – Probability va Actual Vs Predicted
  • Image generation: Noise . gnerator Network > fake Image vs Real image – GAN Loss va Discriminator Loss
  • CNN network help reduce # of parameter
  • Droppot layers can help reduce overfitting
  • validation split of x%chooses last x% of train data
  • Generation of new data is challenging

11:00am

Break

11:15am

Thursday, August 22 • 11:15am – 12:00pm

Rapid Data Science

Most companies today require fast, traceable, and actionable answers to their data questions. This talk will present the structure of the data science process along with cutting edge developments in computing and data science technology (DST) with direct applications to real world problems (with a lot of pictures!). Everything from modeling to team building will be discussed, with clear business applications.

Speakers

avatar for Erez Kaminski

Erez Kaminski

Leaders Global Operations Fellow, MIT
Erez has spent his career helping companies solve problems using data science. He is currently a graduate student in computer science and business at MIT. Previously, he worked in data science at Amgen Inc. and as a technologist at Wolfram Research.

12:00pm

Lunch

1:00pm

Thursday, August 22 • 1:00pm – 1:45pm

Health and Healthcare Data Visualization – See how you’re doing

Health and healthcare organizations are swimming in data but few have the skills to show and see the story in their data using the best practices of data visualization. This presentation raises awareness about the research that inform these best practice and stories from the front of groups who are embracing them and re-imagining how they display their data and information. These groups include the NYC Dept of Health & Mental Hygiene, The Centers for Medicare and Medicaid (CMS), and leading medical centers and providers across the country.

Speakers

avatar for Katherine Rowell

Katherine Rowell

Co-Founder & Principal, Health Data Viz
Katherine Rowell is a health, healthcare, and data visualization expert. She is Co-founder and Principal of HealthDataViz, a Boston firm that specializes in helping healthcare organizations organize, design and present visual displays of data to inform their decisions and stimulate… Read More →
  • dashboard for Hospital CEOs

1:45pm

Break

2:00pm

Thursday, August 22 • 2:00pm – 2:45pm

AI in Healthcare

Benefits, challenges and impact of AI and Cybersecurity on medicine.

Speakers

avatar for Vinit Nijhawan

Vinit Nijhawan

Lecturer, Boston University
Vinit Nijhawan is an Entrepreneur, Academic, and Board Member with a track record of success, including 4 startups in 20 years.
  • US: Spends the most on Health Care (HC) death per 100K people is the highest
  • Eric Topol – Diagnosis is not done correctly, AI will help with diagnosis
  • Diagnosis — AI will have the most impact; VIRAL infections are diagnosed as bacterial infections and get antibiotics for treatment
  • Image Classification my ML – decline below to human misclassification
  • Training Data sets – Big data
  • Algorithms getting better
  • Data Capture getting better – HC as well
  • Investment in HC is the greatest
  • SECURITY related to Implentable Medical Devices = security attacks – hacking and sending signal to implentable devices

2:45pm

Break

3:00pm

Empower

Thursday, August 22 • 3:00pm – 3:30pm

Patient centric AI: Saving lives with ML driven hospital interventions

This presentation will cover the use of machine learning for maximizing the impact of a hospital readmissions intervention program. With machine learning, clinical care teams can identify and focus their intervention efforts on patients with the highest risk of readmission. The talk will go over the goals, logistics, and considerations for defining, implementing, and measuring our ML driven intervention program. While covering some technical details, this presentation will focus on the business implementation of advanced technology for helping people live healthier lives.

Speakers

avatar for Miguel Martinez

Miguel Martinez

Data Scientist, Optum
Miguel Martinez is a Data Scientist at Optum Enterprise Analytics. Relied on as a tech lead in advancing AI healthcare initiatives, he is passionate about identifying and developing data science solutions for the benefit of organizations and people.

 

3:30pm

Break

3:45pm

Thursday, August 22 • 3:45pm – 4:15pm

Using Ontologies to Power AI Systems

There’s a great deal of confusion about the role of a knowledge architecture in artificial intelligence projects. Some people don’t believe that any reference data is necessary. But in reality reference data is required- even if there is no metadata or architecture definitions outside defined externally for an AI algorithm, someone has made the decisions about architecture and classification within the program. However, this will not work for every organization because there are terms, workflows, product attributes, and organizing principles that are unique to the organization and that need to be defined for AI tools to work most effectively.

Speakers

avatar for Seth Earley

Seth Earley

CEO, Earley Information Science
Seth Earley is a published author and public speaker about artificial intelligence and information architecture. He wrote “There’s no AI without IA” which has become an industry catchphrase used by a number of people including Ginny Rometty, the CEO of IBM.
  • Ontology, taxonomies, thesauri – conceptual relationships
  • Object-Oriented Programming and Information Architecture using AI is Old wine in new bottles

4:15pm

Networking Social in Atrium
Thursday, August 22

TBA

 Senior Leadership Panel: Future Directions of Analytics

This panel includes senior leaders from across industry, academia & government to discuss challenges they are tackling, needs they anticipate and goals they will achieve

Moderators

avatar for Bonnie Holub, PhD

Bonnie Holub, PhD

Industry & Business Data Science, Teradata
Bonnie has a PhD in Artificial Intelligence and specializes in correlating disparate sets of Big Data for actionable results.

Read Full Post »

2019 New England Venture Summit, December 4th 2019 at the Hilton in Boston, Dedham, MA, hosted by youngStartUp #NEVS

Posted in BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on July 23, 2019| Leave a Comment »

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

is pleased to announce its sponsorship and invite you to attend

The New England Venture Summit presented by youngStartup Ventures.

@pharma_BI

@AVIVA1950

 #NEVS

Agenda

●●●

Wednesday, December 4th, 2019

8:00 am

CONFERENCE REGISTRATION & CONTINENTAL BREAKFAST
8:50 am

WELCOME REMARKS
9:00 am

THE CHANGING VENTURE WORLD: WHAT CAN WE EXPECT FOR THE NEXT 24 MONTHS?

Venture Capital thought leaders debate the challenges and opportunities facing Investors and Entrepreneurs

Location: Fairbanks Ballroom
9:50 am

BREAK
10:00 am

COMPANY PRESENTATIONS – ROUND I

Track I:   Technology (Charles W. Fairbanks Ballroom)
Track II:  Life Sciences/Healthcare (Grace Ballroom)
Track III: Cleantech (New England Suite)
Track IV: Fintech (Westwood Suite)
Track V:  Seed Pitchfest (Erastus C. Fairbanks Ballroom)
11:00 am

NETWORKING & REFRESHMENT BREAK
11:40 am

COMPANY PRESENTATIONS – ROUND II

Track I:   Technology (Charles W. Fairbanks Ballroom)
Track II:  Life Sciences/Healthcare (Grace Ballroom)
Track III: Cleantech (New England Suite)
Track IV: Fintech (Westwood Suite)
Track V:  Seed Pitchfest (Erastus C. Fairbanks Ballroom)
12:50 pm

LUNCH & NETWORKING (12:50pm – 1:50pm)

Please see below for information on concurrent session running throughout lunch.
1:00 pm

RAISING ANGEL MONEY – INFO & INSIGHTS FROM SEASONED INVESTORS

Location: Grace Ballroom
1:50 pm

COMPANY PRESENTATIONS – ROUND III

Track I:   Technology (Charles W. Fairbanks Ballroom)
Track II:  Life Sciences/Healthcare (Grace Ballroom)
Track III: Cleantech (New England Suite)
Track IV: Fintech (Westwood Suite)
Track V:  Seed Pitchfest (Erastus C. Fairbanks Ballroom)
3:00 pm

CONCURRENT PANELS:

THE ART OF NEGOTIATING TERMS SHEETS

Entrepreneurs who don’t prepare well for term-sheet negotiations may find themselves locked into an uncomfortable relationship with their VC for years to come.  Whether you’re looking for a first-round or follow-up funding, attend this panel to learn what you should know about negotiating term sheets.

Location: Fairbanks Ballroom

ENERGIZING THE FLOW OF CLEAN-TECH DEALS

This session will discuss the trends in the financial markets and the future of venture capital investment in clean-tech.

Location: Grace Ballroom

BANKING ON FIN-TECH INNOVATION

Join top-tier VCs to discuss the rise of fintech, the integration of groundbreaking technologies within financial services, and the future of digital finance.

Location: New England Suite
3:50 pm

NETWORKING & REFRESHMENT BREAK
4:30 pm

CONCURRENT PANELS:

FUNDABLE DEALS: MAKING VCs SIT UP AND TAKE NOTICE

Ideas are all well and good, but in order to attract capital they will need to be packaged and presented in a way that will entice investors and of course a SOLID business model.  This panel will discuss the skills required to make a highly effective pitch that will attract potential financiers and the types of deals investors want.

Location: Grace Ballroom

 

CORPORATE VENTURE CAPITAL: WHAT YOU NEED TO KNOW

With a new flowering of startup innovation, many giants of industry have decided to enter or re-enter the world of VC. This session will explore the value-added investment approach of Corporate VCs and how it yields important dividends that are “beyond the bottom line,” both for the investor and for the startup.

Location: Fairbanks Ballroom

LIFE SCIENCES & HEALTHCARE VC CHECKUP

VCs compare and contrast the growth of seemingly healthy companies. What did these companies do right? Where did they go wrong? Which one would be considered a healthier investment and why? Does your company measure up? What healthy habits will make your company a more desirable investment? Find out if you pass the VC health checkup.

Location: New England Suite
5:20 pm

AWARDS & CLOSING REMARKS
5:30 pm

SUMMIT ADJOURNS

UPDATED on 11/25/2019

 

Last chance to register for The New England Venture Summit presented by youngStartup Ventures.

Special discount.  Use discount code “LPBI-VIP” and receive $100 off the current rates

 

>> Call for Top Innovators to present to leading Investors (details below).

 

New England

Venture Summit

December 4th 2019 | Hilton | Boston, Dedham

 

Where Innovation Meets Capital

 

 

Friends,

 

Come meet, interact and network with hundreds of VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the Lifesciences/Healthcare Track at the prestigious New England Venture Summit being held on December 4th 2019 at the Hilton in Boston, Dedham.

 

Whether you’re a Lifescience/Healthcare startup seeking capital and exposure, or a Biotech investor seeking new deals, The New England Venture Summit presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, the Lifesciences/Healthcare track at The New England Venture Summit is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 

Partial List of over 150 VCs & Angel Investors confirmed to speak and judge includes:Anil Achyuta, Investment Director, TDK Ventures | Omair Ahmed, Associate, Echo Health Ventures | Navneet Alag, Vice President, H.I.G. BioHealth Partners | Dave Anderson, Managing General Partner, Supply Chain Ventures | Mark Austin, Managing Director, Viridian Capital | Shannon Austin, Partner, Financial Venture Studio | Natalie Bartlett, Investor, General Catalyst | Anna Batarina, Partner, Apple Tree Partners | Kyle Beatty, Principal, American Family Ventures | Anthony Bellafiore, Associate, LaunchCapital | Ned Berman, Senior Associate, Samsung Catalyst Fund | Matt Bloom, Investment Director, Connecticut Innovations | Carsten Boers, Managing Partner, Rhapsody Venture Partners | Greg Bohlen, Managing Director, Union Grove Venture Partners | Caitlin Bolnick, Investor, OpenView Venture Partners | Lee Bouyea, Managing Director, Fresh Tracks Capital | Maureen Boyce, Managing Partner, Good Growth Capital | Eric Breese, Investment Manager, Evonik Venture Capital | Nathaniel Brinn, Partner, VC23 Investors | Brendan Brits, Investor, Bertelsmann Digital Media Investments | Peter Bruce-Clark, Partner, Social Impact Capital | Ciara Burnham, Partner, QED Investors | Daniel Burstein, Managing Partner, Millennium Technology Value Partners | Jeffrey Carter, General Partner, West Loop Ventures | Kathryn Cartini, Partner, Chloe Capital | Anup Chamrajnagar, Investor, Point72 Ventures | Sean Cheng, Investment Manager, Philips Ventures | Ian Chiang, Principal, Flare Capital Partners | Elizabeth Cho-Fertikh, Co-Founder & Managing Director, MEDA Angels | Andrew Clapp, Managing Director, CIG CAP | Iain Cooper, Manager Corporate Ventures, Schlumberger Technology Investments | Mark Cupta, Partner, Prelude Ventures | John Curtin, Associate, Waterline Ventures | Kapil Desai, Vice President, Catalyst Investors | Damien Despinoy, Director, Energy Foundry | Dan Doble, Managing Director, SABIC Ventures | Lisa Dolan, Principal, Link Ventures | Tyler Durham, Principal, Schlumberger Technology Investments | Laura Easton, Analyst, Real Ventures | Jonathan Friedlander, Principal, Digitalis Ventures | Lisa Frusztajer, Lead Investor, Portfolia Enterprise Fund | Ernestine Fu, Venture Partner, Alsop Louie Partners | Stan Fung, Managing Director, FarSight Ventures | Robert Garber, Partner, 7wire Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Elianna Goldstein, Analyst, Boeing HorizonX Ventures | Alex Golod, Angel Investor, Chicago ArchAngels | Emilia Gonzalez, Principal, Joyance Ventures | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | Edward Greer, Corporate Technology Scout, Dow Ventures | Vicky Guo, Investment Director, Pearson Ventures | Robert Hamlin, Principal, Portag3 Ventures | Jana Hanova, Director, Evok Innovations | Sven Harmsen, Director External Ventures, NOVA External Ventures Saint-Gobain | Andrew Hartford, Managing Partner, Hartford Lab | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Kaitlyn Henry, Associate, OpenView Venture Partners | Chris Ho, Vice President, Vickers Venture Partners | Toan Huynh, Partner, Information Venture Partners | Ben Jen, CEO & Angel Investor, Ben Jen Holdings LLC | Del Johnson, Principal, Backstage Capital | Jay Karandikar, Venture Partner, New Crop Capital | Madeline Keulen, Vice President, Victress Capital | Roman Kikta, Managing Partner & Founder, Mobility Ventures | Frank Klemens, Managing Director, DuPont Ventures | Jak Knowles, Vice President Venture Investments, Leaps by Bayer | Diana Kontsevaia, Investor, Dell Technologies Capital | Ventures | Luda Kopeikina, Investment Director, DSM Venturing | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ed Lafferty, Partner & CFO, Saturn Partners | Logan Langberg, Principal, Imaginary Ventures | Tiffany Le, Investor, Kaiser Permanente Ventures | James Lee, Investment Associate Director, Photon Fund | Claire Leurent, Managing Director, Samsung Ventures | Debbie Lin, Executive Director & Investment Manager, Boehringer Ingelheim Venture Fund | Darwin Ling, Founding General Partner, Good AI Capital | Jim Lockheed, Investment Associate, JetBlue Technology Ventures | Mary Long-Irwin, Executive Director, Northern Ontario Angels | Bion Ludwig, Partner, Savano Capital Partners | Josh Lumer, Senior Associate, Allstate Strategic Ventures | Alan MacIntosh, General Partner, Real Ventures | Wasim Malik, Managing Partner, Iaso Ventures | Ricky Margolis, VP of Business Development, ARIE Capital | Hollis McGuire, Director, Impact NH Fund | Theo Mendez, Investor, Insight Partners | Philip Mertens, Investment Analyst, DSM Venturing | Sarah Millar, Associate, City Light Capital | David Miller, Co-Founder and Managing Director, Clean Energy Ventures | Mark Miller, Managing Partner, Good Harbor Partners | Yiannis Monovoukas, Co-Founder & Managing Partner, SpringTide Ventures | Craig Mullett, Director, Angel Investor Forum | Jared Newman, Associate, Betawork Ventures | Clay Norris, Investment Associate, Carolinas Fintech Ventures | Michael Pachos, Head of East Coast / Managing Director, Samsung Ventures | Akhilesh Pathipati, Principal, MVM Partners | Charles Paul, Vice President – Technology, Henkel Ventures | Caroline Pelletier, Angel Investor, Anges Québec | Mike Perry, Investment Associate, Link Ventures | Damien Petty, Principal, Morpheus Ventures | Lauren Michelle Pfeifer, Principal, Maschmeyer Group Ventures | Benjamin Price, Venture Manager, NOVA External Ventures Saint-Gobain | Suraj Kumar Rajwani, Co-Founder and Partner, DoubleRock Venture Capital | Ashley Ramirez, Investor & Chief of Staff, Halogen Ventures | Jeff Ransdell, General Partner, Rokk3r Fuel ExO | Wanda Reindorf, Managing Director, Clean Energy Venture Group | Alison Andrews Reyes, General Partner, 1843 Capital | Lisa Rhoads, Managing Director, Easton Capital Investment Group | Candace Richardson, Senior Associate, Town Hall Ventures | Mark Robinson, Founder and Managing Director, WAVE Equity Partners | Gus Roman, Venture Capital Associate, Global Founders Capital | Rob Rosenberg, Partner, Prolog Ventures | Brita Rosenheim, Partner, Better Food Ventures | Robert Rothman, Founder and Managing Member, InFocus Capital Partners | Tayo Sanders, Associate, Anzu Partners | Sugam Sarin, Investment Manager, American Express Ventures | Jennifer Schretter, Partner, PROOF VC | Brian Schuman, Associate Manager, PepsiCo Technology Ventures | Paul Seidler, Managing Director, Clean Energy Trust | Shantnu Sharma, Managing Director, AMD Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Jean Sini, Angel Investor | Matt Snow, Analyst, Greenspring Associates | Vivek Soni, Venture Partner, S Cap Cleantech Fund | Adarsh Sowcar, External Ventures Manager, NOVA External Ventures Saint-Gobain | Joseph Spivack, Angel Investor | Lindsay Karas Stencel, Managing Partner, Gravity Ventures | Lutz Stoeber, Investment Director, Evonik Venture Capital | Neil Swami, Principal, Catalyst Health Ventures | Byron Thom, Principal, Framework Venture Partners | Michael Thomas, Investment Director, Inova Health System Strategic Investments | Alexander Urban, Associate, Shell Ventures | Claude Vachet, Managing Partner, Cycle Capital Management | Erica Van, Investor, Charles River Ventures | Kutral Veerabadran, Principal, Flow Capital | Sonali Vijayavargiya, Managing Director, Augment Ventures | Patrick Walsh, Director, National Grid Partners | George Wang, Associate, Global Founders Capital | Raymond Wang, Investor, Two Sigma Ventures | John Wei, Senior Investment Manager, SABIC Ventures | Jeffrey Weiss, Senior Venture Partner, Clean Energy Ventures | Catherine Friend White, Managing Director, Golden Seeds | Henry White, Venture Partner, Good Growth Capital | Alex Whitney, Senior Analyst, ManchesterStory Group | Jacqueline Wibowo, Investor, Insight Partners | Tom Wisniewski, Co-Founder & Managing Partner, Newark Venture Partners | Joanne Wong, General Partner, REDDS Capital | Zac Yu, Investor, Magnet Ventures | Greg Zaic, Principal and General Partner, NMT Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Sebastian Zhou, Investor, Alpha Square Group | Chris Zock, Managing Director, Sandbox Insurtech Ventures and many more…

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive $100 off the current rates.

This conference will be attended by the best people in the industry. Please register asap to avoid disappointment. 

 

Register Today & Save Click here.   (Use promo code “LPBI-VIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 150 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

We look forward to seeing you there. 

 

Leaders in Pharmaceutical Business Intelligence & youngStartup Ventures

@@@@@

Special discount offered   

Use discount code “LPBI-VIP“ and receive 10% off the “early bird” rates.

 

Call for Top Innovators to present to leading Investors (details below).

 

New England Venture Summit

December 3rd & 4th 2019 | Hilton | Boston, Dedham

Where Innovation Meets Capital

 

 http://bit.ly/2M8rxzd

UPDATES

From: “Gil Garalnick [FinTrack Venture Summit]” <Gil@youngstartup.com>

Date: Monday, October 7, 2019 at 3:45 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: Industry Partnership Update: New England Venture Summit

 

Hi Aviva –

 

Pleased to share an updated list of over 100 VCs and Angels confirmed to speak.

 

Early bird rates end October 31st. Would it feasible to share an update with your network? I can send over updated copy.

 

Partial List of over 100 VCs & Angel Investors confirmed to speak and judge includes:

Anil Achyuta, Investment Director, TDK Ventures | Omair Ahmed, Associate, Echo Health Ventures | Mark Austin, Managing Director, Viridian Capital | Natalie Bartlett, Investor, General Catalyst | Ned Berman, Senior Associate, Samsung Catalyst Fund | Carsten Boers, Managing Partner, Rhapsody Venture Partners | Greg Bohlen, Managing Director, Union Grove Venture Partners | Caitlin Bolnick, Investor, OpenView Venture Partners | Eric Breese, Investment Manager, Evonik Venture Capital | Brendan Brits, Investor, Bertelsmann Digital Media Investments | Ciara Burnham, Partner, QED Investors | Daniel Burstein, Managing Partner, Millennium Technology Value Partners | Jeffrey Carter, General Partner, West Loop Ventures | Kathryn Cartini, Partner, Chloe Capital | Anup Chamrajnagar, Investor, Point72 Ventures | Sean Cheng, Investment Manager, Philips Ventures | Elizabeth Cho-Fertikh, Co-Founder & Managing Director, MEDA Angels | Andrew Clapp, Managing Director, CIG CAP | Iain Cooper, Manager Corporate Ventures, Schlumberger Technology Investments | Mark Cupta, Partner, Prelude Ventures | Kapil Desai, Vice President, Catalyst Investors | Damien Despinoy, Director, Energy Foundry | Dan Doble, Managing Director, SABIC Ventures | Jesse Draper, Founding Partner, Halogen Ventures | Tyler Durham, Principal, Schlumberger Technology Investments | Laura Easton, Analyst, Real Ventures | Jonathan Friedlander, Principal, Digitalis Ventures | Lisa Frusztajer, Lead Investor, Portfolia Enterprise Fund | Stan Fung, Managing Director, FarSight Ventures | Robert Garber, Partner, 7wire Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Emilia Gonzalez, Principal, Joyance Ventures | Ajay Gopal, Founding Principal, Framework Venture Partners | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | Edward Greer, Corporate Technology Scout, Dow Ventures | Vicky Guo, Investment Director, Pearson Ventures | Brooke Hammer, Associate, F-Prime Capital | Jana Hanova, Director, Evok Innovations | Andrew Hartford, Managing Partner, Hartford Lab | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Kaitlyn Henry, Associate, OpenView Venture Partners | Jay Karandikar, Venture Partner, New Crop Capital | Madeline Keulen, Vice President, Victress Capital | Roman Kikta, Managing Partner & Founder, Mobility Ventures | Frank Klemens, Managing Director, DuPont Ventures | Diana Kontsevaia, Investor, Dell Technologies Capital | Ventures | Luda Kopeikina, Investment Director, DSM Venturing | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Logan Langberg, Principal, Imaginary Ventures | James Lee, Investment Associate Director, Photon Fund | Claire Leurent, Managing Director, Samsung Ventures | Darwin Ling, Founding General Partner, Good AI Capital | Jim Lockheed, Investment Associate, JetBlue Technology Ventures | Mary Long-Irwin, Executive Director, Northern Ontario Angels | Wasim Malik, Managing Partner, Iaso Ventures | Hollis McGuire, Director, Impact NH Fund | Sarah Millar, Associate, City Light Capital | Craig Mullett, Director, Angel Investor Forum | Jared Newman, Associate, Betawork Ventures | Clay Norris, Investment Associate, Carolinas Fintech Ventures | Mike Perry, Investment Associate, Link Ventures | Lauren Michelle Pfeifer, Principal, Maschmeyer Group Ventures | Jeff Ransdell, General Partner, Rokk3r Fuel ExO | Wanda Reindorf, Managing Director, Clean Energy Venture Group | Alison Andrews Reyes, General Partner, 1843 Capital | Lisa Rhoads, Managing Director, Easton Capital Investment Group | Mark Robinson, Founder and Managing Director, WAVE Equity Partners | Gus Roman, Venture Capital Associate, Global Founders Capital | Rob Rosenberg, Partner, Prolog Ventures | Tayo Sanders, Associate, Anzu Partners | Jennifer Schretter, Partner, PROOF VC | Reese Schroeder, Managing Director, Tyson Ventures | Paul Seidler, Managing Director, Clean Energy Trust | Shantnu Sharma, Managing Director, AMD Ventures | Jean Sini, Angel Investor | Vivek Soni, Venture Partner, S Cap Cleantech Fund | Joseph Spivack, Angel Investor | Alex Steiner, Investment Analyst, Anthemis Group | Lutz Stoeber, Investment Director, Evonik Venture Capital | Neil Swami, Principal, Catalyst Health Ventures | Alexander Urban, Associate, Shell Ventures | Claude Vachet, Managing Partner, Cycle Capital Management | Erica Van, Investor, Charles River Ventures | Patrick Walsh, Director, National Grid Partners | Raymond Wang, Investor, Two Sigma Ventures | Greg Zaic, Principal and General Partner, NMT Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Sebastian Zhou, Investor, Alpha Square Group | Chris Zock, Managing Director, Sandbox Insurtech Ventures and many more…

 

Look forward to hearing from you.

 

 

Regards

 

Gil

 

Gil Garalnick

Associate 
youngStartup Ventures
“Where Innovation Meets Capital”

 

p: 212.202.1002

e: gil@youngstartup.com

u: www.youngstartup.com

 

Friends,

 

Come meet, interact and network with hundreds of VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the Lifesciences/Healthcare Track at the prestigious New England Venture Summit being held on December 3rd & 4th 2019 at the Hilton in Boston, Dedham.

 

Whether you’re a Lifescience/Healthcare startup seeking capital and exposure, or a Biotech investor seeking new deals, The New England Venture Summit presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, the Lifesciences/Healthcare track at The New England Venture Summit is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 UPDATED on 8/27/2019

 

VCs & Angel Investors confirmed to speak and judge includes:

Mark Austin, Managing Director, Viridian Capital | Greg Bohlen, Managing Director, Union Grove Venture Partners | Ciara Burnham, Partner, QED Investors | Jeffrey Carter, General Partner, West Loop Ventures | Kathryn Cartini, Partner, Chloe Capital | Anup Chamrajnagar, Investor, Point72 Ventures | Andrew Clapp, Managing Director, CIG CAP | Iain Cooper, Manager Corporate Ventures, Schlumberger Technology Investments | Jesse Draper, Founding Partner, Halogen Ventures | Tyler Durham, Principal, Schlumberger Technology Investments | Robert Garber, Partner, 7wire Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Emilia Gonzalez, Principal, Joyance Ventures | Ajay Gopal, Founding Principal, Framework Venture Partners | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Kaitlyn Henry, Associate, OpenView Venture Partners | Jay Karandikar, Venture Partner, New Crop Capital | Roman Kikta, Managing Partner & Founder, Mobility Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Darwin Ling, Founding General Partner, Good AI Capital | Sarah Millar, Associate, City Light Capital | Craig Mullett, Director, Angel Investor Forum | Jared Newman, Associate, Betawork Ventures | Lauren Michelle Pfeifer, Principal, Maschmeyer Group Ventures | Lisa Rhoads, Managing Director, Easton Capital Investment Group | Mark Robinson, Founder and Managing Director, WAVE Equity Partners | Tayo Sanders, Associate, Anzu Partners | Reese Schroeder, Managing Director, Tyson Ventures | Paul Seidler, Managing Director, Clean Energy Trust | Jean Sini, Angel Investor | Vivek Soni, Venture Partner, S Cap Cleantech Fund | Alex Steiner, Investment Analyst, Anthemis Group | Claude Vachet, Managing Partner, Cycle Capital Management | Erica Van, Investor, Charles River Ventures | Raymond Wang, Investor, Two Sigma Ventures | Greg Zaic, Principal and General Partner, NMT Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Chris Zock, Managing Director, Sandbox Insurtech Ventures and many more…

 

Lineup of over 120 VCs & Angels that spoke and judged at NEVS18 includes:

Karine Agajanian, Analyst, Anzu Ventures | Sanjay Aggarwal, Venture Partner, F-Prime Capital Partners | Magdi Amin, Investment Partner, Omidyar Network | Peter Arkell, Investor, Norwest Venture Partners | Mark Austin, Partner, Bright Capital | Salman Azhar, Managing Director, Duke Angel Network | Ibraheem Badejo, Sr. Director, Johnson & Johnson Innovation | Sunny Bai, Associate, CRCM Ventures | Janet Bannister, Partner, Real Ventures | Peter Bastien, Partner, Next47 | Alex Beletsky, Investor, Sidecar Angels | Woody Benson, Venture Partner, Launch Capital | Joshua Berg, Investment Manager, GM Ventures | Raghav Bhargava, Associate, NEA | Victor Bian, Associate, Intellectual Ventures | Laura Bock, Investor, QED Investors | Nabil Borhanu, Managing Partner, Graphene Ventures | Will Borthwick, Senior Associate, Bold Capital Partners | Lee Bouyea, Managing Director, FreshTracks Capital | Eric Breese, Managing Director, Evonik Venture Capital | Maxx Bricklin, Founding Principal, Bold Capital Partners | Dan Burstein, Managing Partner, Millennium Technology Value Partners | Jason Cahill, Founder & Managing Director, McCune Capital | Neil Callahan, Co-Founder and Managing Director, Pilot Growth Equity | Efayomi Carr, Associate, Quona Capital | Sara Chamberlain, Managing Director, Energy Foundry | Raymond Chang, Managing Director, NXT Ventures | Christopher Chu, Managing Director, Samsung Catalyst Fund | Meghan Cross Breeden, Managing Partner, Red Bear Angels | David Cruikshank, Partner, ARCH Venture Partners | Sophia Dardashti, Associate, WorldQuant Ventures | Ekaterina Dorozhkina, Managing Partner, Starta Ventures | Miriam Eaves, Venture Partner, BP Ventures | Kathryn Meng Elmes, Investment Associate, Massachusetts Clean Energy Center | Alison Ernst, Senior Manager of Investments, Massachusetts Clean Energy Center | Teresa Esser, Managing Director, Silicon Pastures | Michael Fanfant, Investor, Runa Capital | David Feldman, Analyst, Indicator Ventures | Mark G. Fields, Partner, Alsop Louie Partners | Shawn Flynn, Investment Director, Bay Angels | Prashant Fonseka, Principal, Tuesday Capital | Haley Fradkin, Investment Associate, Plum Alley | Lisa Frusztajer, Investor, Portfolia Enterprise Fund | Kyle Fugere, Head of Ventures, dunnhumby Ventures | Matt Gatto, Partner, Insight Venture Partners | Joy Ghosh, Investor, Bain Capital Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Jamil Goheer, Managing Partner & Cofounder, CoVenture | Ben Gorman, Associate, F-Prime Capital Partners | Edward Greer, Corporate Technology Scout, Dow Ventures | Jacob E. Grose, Investment Manager, BASF Venture Capital | Zain Gulamali, Investor, Amazon Alexa Fund | Marina Hadjipateras, Co-Founder & General Partner, Trail Mix Ventures | Hunter Hartwell, Principal, Forte Ventures | Laurence Hayward, Founding Partner, Independence Equity | Nathaniel Henshaw, Managing Director, CEI Ventures | Michael Hoeksema, Associate, Battery Ventures | Lindsay Hyde, Venture Partner, Moderne Ventures | Oren Isacoff, Principal, Longitude Capital | Nicolas Jacques-Bouchard, Principal, Panache Ventures | Jamie James, Managing Partner, GreenSoil Building Innovation Fund | Noel Jee, Investor, Illumina Ventures | Lacey Johnson, Principal, Green D Ventures | Ajay Kamat, Managing Director, Pear Ventures | Alex Kaufman, Investment Associate, JetBlue Technology Ventures | Shane Kelly, Head of Investments, CrowdSmart | Patrick Kenealy, Managing Director, Ridge Ventures | Jack Kerrigan, Managing Director, Razor’s Edge Ventures | Jonathan Kerstein, Associate, Red Sea Ventures | Nyla Koncurat, Managing Partner, Karlani Capital | Daniel Kwak, Investor, Point72 Ventures | Vivek Ladsariya, Partner, SineWave Ventures | Donna Lecky, Managing Director, Health Venture Capital | Linus Liang, Senior Associate, Signia Venture Partners | Bion Ludwig, Partner, Savano Capital Partners | Kyle Lui, Principal, DCM Ventures | Tamim Abdul Majid, Principal, OCA Ventures | Nurzhas Makishev, Managing Partner, NKM Capital | Eller Mallchok, Managing Director, Jumpstart Foundry | Coppelia Marincovic, Investment Manager, Solvay Ventures | Olga Maslikhova, Managing Partner, Phystech Ventures | Tom Mastrobuoni, Chief Financial Officer, Tyson Ventures | Hiroki Matsuda, Investor, Sozo Ventures | Derek Mazur, Senior Associate, Sante Ventures | David Miller, Co-Founder and Managing Director, Clean Energy Ventures | Julia Moore, Partner, Breakout Ventures | Kirsten Morbeck, Managing Director, SpringRock Ventures | Amit Mulgaonkar, Investor, Mithril Capital Management | Sheila Narayan, Managing Director, Golden Seeds | David Nault, General Partner, Luge Capital | Sara M. Nayeem, Partner, NEA | Brian Panoff, Senior Principal, Shell Ventures | Sumay Parikh, Principal, Quake Capital | Daniel Povitsky, Vice President, Sinai Ventures | Vinny Pujji, Investor, Insight Venture Partners | Venu Raghavan, Vice President, Wasson Enterprise | Gopal Rajaraman, Investment Principal , Motorola Solutions Venture Capital | Wanda Reindorf, Managing Director, Clean Energy Ventures | Brendan Rempel, Associate, OpenView Venture Partners | Martin Ringlein, Venture Partner, NextGen Venture Partners | Praveen Sahay, Managing Director, WAVE Equity Partners | Louis Schick, Founding Partner, NewWorld Capital Group | Chris Seitz, Associate, Excel Venture Management | Connie Sheng, Founding Managing Partner, Nautilus Venture Partners | Alex Shtarkman, Associate, Revolution | John Simon, Managing Director, Sigma Prime Ventures | Sidarth Singh, Investor, Stripes Group | Emily Snyder, Associate, Borealis Ventures | Vivek Soni, Managing Director, TiE-Boston Angels | Siri Srinivas, Associate, Draper Associates | Luisa Sucre, Associate, Revolution | Lyndsey Toeppen, Vice President, Sandbox Insurtech Ventures | Tibor Toth, Managing Director, Massachusetts Clean Energy Center | Laurel Touby, Partner, Supernode Ventures | Chisom Uche, Associate, SixThirty | Alexander Urban, Principal, Shell Ventures | Claude Vachet, Managing Partner, Cycle Capital Management | Maria Velissaris, Investor, Pipeline Angels | Anthony Walsh, Principal, BioInnovation Capital | John Wei, Sr. Investment Manager, SABIC Ventures | Jamie M. Weston, Managing Director, Spring Mountain Capital | Christopher J. Whalen, Managing Director, New Technology Ventures | Thomas Whiteaker, Partner, Propel Venture Partners | Jillian Williams, Investor, Anthemis Group | Troy Williams, Managing Director, University Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Sanjay Zimmermann, Associate, White Star Capital and many more.

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence (LPBI) Group has made special arrangement for our network to receive a special discount of 10% off the existing “early bird” savings.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 

 

Register Today & Save Click here.   

(Use promo code “LPBI-VIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators from the Life Sciences/Healthcare sector will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for our Seed stage track.

 

We look forward to seeing you there. 

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

&

youngStartup Ventures

 

REAL TIME Press Coverage for

 http://pharmaceuticalintelligence.com 

by

 Aviva Lev-Ari, PhD, RN

Director & Founder, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief, Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com

Editor-in-Chief, BioMed e-Series, 16 Volumes in Medicine, https://pharmaceuticalintelligence.com/biomed-e-books/

@pharma_BI

@AVIVA1950

 #NEVS

 

Logo, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Our BioMed e-series

WE ARE ON AMAZON.COM

https://lnkd.in/ekWGNqA

2019 New England Venture Summit, December 3rd & 4th 2019 at the Hilton in Boston, Dedham, MA, hosted by youngStartUp #NEVS

 

AGENDA

Wednesday, December 4th, 2019

8:00 am

CONFERENCE REGISTRATION & CONTINENTAL BREAKFAST
8:50 am

WELCOME REMARKS
9:00 am

THE CHANGING VENTURE WORLD: WHAT CAN WE EXPECT FOR THE NEXT 24 MONTHS?

Venture Capital thought leaders debate the challenges and opportunities facing Investors and Entrepreneurs
9:50 am

BREAK
10:00 am

COMPANY PRESENTATIONS – ROUND I
11:00 am

NETWORKING & REFRESHMENT BREAK
11:40 am

COMPANY PRESENTATIONS – ROUND II
12:50 pm

LUNCH & NETWORKING
1:00 pm

RAISING ANGEL MONEY – INFO & INSIGHTS FROM SEASONED INVESTORS
1:50 pm

COMPANY PRESENTATIONS – ROUND III
3:00 pm

FUNDABLE DEALS: MAKING VCs SIT UP AND TAKE NOTICE

Ideas are all well and good, but in order to attract capital they will need to be packaged and presented in a way that will entice investors and of course a SOLID business model.  This panel will discuss the skills required to make a highly effective pitch that will attract potential financiers and the types of deals investors want.
3:00 pm

ENERGIZING THE FLOW OF CLEAN-TECH DEALS

This session will discuss the trends in the financial markets and the future of venture capital investment in clean-tech.
3:00 pm

ABCs ON ED-TECH INNOVATION & FUNDING

Ed-tech Investors will take center stage to grade the Ed-tech sector and share insights on the trends they’re seeing.
3:50 pm

NETWORKING & REFRESHMENT BREAK
4:30 pm

THE ART OF NEGOTIATING TERMS SHEETS

Entrepreneurs who don’t prepare well for term-sheet negotiations may find themselves locked into an uncomfortable relationship with their VC for years to come.  Whether you’re looking for a first round or follow-up funding, attend this panel to learn what you should know about negotiating term sheets.
4:30 pm

CORPORATE VENTURE CAPITAL: WHAT YOU NEED TO KNOW

With a new flowering of startup innovation, many giants of industry have decided to enter or re-enter the world of VC. This session will explore the value-added investment approach of Corporate VCs and how it yields important dividends that are “beyond the bottom line,” both for the investor and for the startup.
5:20 pm

AWARDS & CLOSING REMARKS
5:30 pm

SUMMIT ADJOURNS

SPEAKERS

https://youngstartup.com/newengland2019/#speakers-sec

Read Full Post »

eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

Posted in Conference Coverage with Social Media, Personalized and Precision Medicine & Genomic Research on July 19, 2019| Leave a Comment »

eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA

 

The 15th Annual Personalized Medicine Conference at Harvard Medical School will explore the science, business, and policy issues facing personalized medicine as scientists refine their understanding of how groundbreaking molecular diagnostics augmented by artificial intelligence, advanced data analytics, and digital health applications can empower both physicians and patients with information about how an expanded set of biological characteristics — including those found in the proteome and microbiome — may influence their health and their responses to increasingly impactful therapies.

 

WELCOME RECEPTION – NOVEMBER 13, 2019 – 6:15 P.M.

at the Isabella Stewart Gardner Museum, 25 Evans Way, Boston, MA 02115

http://www.personalizedmedicineconference.org/schedule/

 

Dear Colleague:

Use the link to access videos of the keynote sessions

featuring Scott Gottlieb, M.D., of the American Enterprise

Institute; Carl June, M.D., of the University of Pennsylvania;

Steven Shak, M.D., of Genomic Health; and Paul Stoffels,

M.D., of Johnson & Johnson.

As senior leaders from the GO2 Foundation for Lung Cancer, Harvard Pilgrim Health Care, the Institute for Clinical and Economic Review, M2Gen, and Novartis walked off the stage after the 15th Annual Personalized Medicine Conference at Harvard Medical School‘s final session, which was titled “Toward a Shared Value Proposition in Health Care,” Natasha Loder, Health Policy Editor, The Economist, told me it was “remarkable” to “see all of these people discuss the issues together” as she prepares to write a feature story on personalized medicine.

Her comments capture the spirit of this year’s conference and speak to PMC’s approach to advancing personalized medicine.

From: “Christopher Wells (PMC)” <cwells@personalizedmedicinecoalition.org>

Reply-To: “Christopher Wells (PMC)” <cwells@personalizedmedicinecoalition.org>

Date: Thursday, November 21, 2019 at 2:05 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Thank You for Joining Us

ANNOUNCEMENT

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in Real Time for pharmaceuticalintelligence.com 

In attendance generating in realtime event’s eProceeding and social media coverage by

 

Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

#PMConf

@pharma_BI

@AVIVA1950

AGENDA

Schedule

PART I

Diagnosing, Different

8:00 a.m.
Registration and Breakfast

Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115

8:50 a.m.
Opening Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

  • 170 drugs with biomarkers, up 15% from 2000 in Biomarker strategy
  • Gene therapy started in 2005, today personalized medicine is becoming standard of care.
  • Science & Technology need additional friendly environment for market penetration into care delivery
8:55 a.m.
Welcoming Remarks

SPEAKER | Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School

  • 15th Annual meeting is at a historic moment in Boston where Prof. Church launched the Human Genome Project and Eric Launder at MIT and the Cancer Genome Project.
  • Genzyme conceived gene therapy sold to Sanofi for $ Billion
  • Foundation Medicine acquired by Roche for $ Billion
  • Cystic Fibrosis – therapy discovery in Boston
  • MGH, Dana Farber, Lung Cancer discovery in 2004 theraphy PD-1
  • BWH, Dana Farber, sequence every patient at DF and treatment is guided by the genomic profile
  • 1993 was Millianum start, today Takeda – genetics in disease, initiated PMC
  • Promote Personalized Medicine by the Annual conference, now 15th in a row – promotion of PM is continuing in MA and beyond
  • Case studies at HBS – Kraft Center for Personalized Medicine
9:00 a.m.
The Era of the ‘Living Drug:’ A Keynote Conversation With Dr. Carl June, Pioneer of CAR T-cell Therapy

During this opening keynote session, the University of Pennsylvania’s Dr. Carl June, the discoverer of the chimeric antigen receptor (CAR) T-cell therapies that are unlocking a new era of personalized cancer care, will join Immatics US Chief Medical Officer Dr. Stephen L. Eck for a wide-ranging conversation about the future of personalized medicine, touching on issues including but not limited to access and affordability, regulation and manufacturing, and T-cell therapies beyond cancer.
» Read More

MODERATOR | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics US

Carl June, M.D., Richard W. Vague Professor in Immunotherapy, University of Pennsylvania

  • 1997 first patient treated – 15 years follow up CAR-T cells survived, 3 patient were infused, 2 out of 3 leukemia cell free.
  • Children vs Adults 2011 reported better results in Adults, children’s immune system is evolving
  • In 2019 – 13 biotech companies in CAR-T cell therapies, Gene therapy is growing
  • FDA, drug cycle T cells vs stem cells: engineering T cells life farming – innovation is the driver, FDA is evolving in handling patents involved in Cell engineering
  • Regulatory science needs to evolve in light of gene therapy in Human cell line in China has investments government and VC backed,
  • Similarity between Transfusion Medicine industry and Cell therapy – Transfection of cells therapy
  • Manufacturing of Cells for transfection: Over regulation like in small molecules vs too little regulation
  • Cost of cell transfection therapy: Cost of Goods, Cost of Labor – pay for performance,
  • Manufacture in NJ shipped to Europe – not effective
  • Beyond Cancer: Chronic diseases have systemic of specific immune or autoimmune components: CNS, neurodegenerative and Diabetes, Sickle cell anemia – treatment by cell therapy microphages
  • Diagnostics innovations: Epigenetics, cell sequencing,
  • Liability of a product that everyone wants: Class action law suit,
  • N of 1,
  • China ahead of US, Europe is behind US
  • How to fund and how to transfer from University Hospitals to community Hospital.
9:45 a.m.
Transformative Technologies: Previewing the Value Proposition and Outlook for Disruptive Tools Designed to Enable Personalized Medicine

Emerging personalized medicine technologies may help facilitate earlier interventions that eliminate the need for expensive treatment of advanced diseases that have devastating consequences for patients. They can also help target treatments to only those patients who will benefit. But the success of these technologies depends on whether they can be integrated into a health system that has historically focused on treating diseases after symptoms have intensified, usually based on the assumption that every patient taking a given medication will respond to the treatment in a similar way.

During this session, Section 32 Managing Partner Dr. Michael J. Pellini will moderate a discussion between industry representatives and a payer about the value proposition and outlook for disruptive technologies that are designed to support more informed disease prevention and treatment plans. The conversation will focus on how developments in areas including but not limited to artificial intelligence, data analytics, genomic sequencing, liquid biopsies, and proteomics may impact the prevention, diagnosis, and treatment of diseases including cancer, cardiovascular diseases, and diabetes.
» Read More

MODERATOR | Michael J. Pellini, M.D., Managing Partner, Section 32

  • surgery, chemo, radiation – cost, harmful, INEFFECTIVE, Dr. Reza Columbia Medical School Oncologist 35 years
  • How are we doing with technology? Very remarkable
  • Clinical Utility to the Payer
  • Regulatory – a super star in ten years, Dr. Gottlieb
  • Diagnostics
  • Pain  management
  • Patients can fight more broadly
  • F for sharing data and data exchange
  • 80% patients do not access Academic Centers for treatment
  • Challenge: Not each Payer needs to partner – need for a “coalition” of Payers
  • Standards: Will Payers welcome Government to provide guides – SHARING DATA is a guideline from the Government, i.e., Cystic Fibrosis where data was shared the most – success achieved faster

 

Steven J. Kafka, Ph.D., Partner, Third Rock Ventures; Executive Chairman, Thrive Earlier Detection

  • ex-Millenium, ex-Foundations,
  • Earlier detection of multiple cancers in Healthy individuals, Blood test – developed at John Hopkins, negative vs positive survival curve, early vs late stage
  • genetic profiling genotype used with the Blood test

Nancy Mendelsohn, M.D., Chief Medical Officer, Special Needs Initiative, UnitedHealth Group

  • Pediatrician
  • 2years with UniterHealthCare
  • Better outcome from more expensive treatment is justified
  • How to make effective treatment to rural areas, populations without access

Eric Schadt, Ph.D., CEO, Sema4

  • Spun off Mount Sinai 2 years ago, transfer of innovations to patients is slow, deriving insight is not easy
  • COmplications of pregnancy

Roy Smythe, M.D., CEO, SomaLogic

  • Access to technology and equity is an issue, delivery of care was pure,
  • SomaLogic, measurement of protein expression, applied to predict risk for future disease
  • Many Omics companies, Payers will bet on whom?
  • Standards
10:45 a.m.
Networking Break
11:15 a.m.
Developing Diagnostics — Opportunities and Challenges in Personalized Medicine: A Two-Part Discussion

Diagnostic test developers are working to make personalized medicine possible by giving physicians tools that help them select the optimal treatment for every patient. Doing so requires that they navigate a complex business and policy landscape while being mindful of the day-to-day needs of payers and health care providers.

In this context, Mr. Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific, will take 10 minutes to introduce this two-part discussion titled “Developing Diagnostics — Opportunities and Challenges in Personalized Medicine.”

INTRODUCTION | Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

  • Context: Therapy selection in personalized medicine navigate diagnostics in use and policies when implementations is considered
  • Physicians need precise testing now
  • Payers – evidence of utility is needed
  • Patient Outcome – Data analytics, ML, AI for genomics, proteomics, metabolomics,
  • Tests must be precise and inform the diagnosis by diagnostics
  • Solutions are
  1. Chemical testing
  2. Immune therapy testing
  3. test utilization
  4. test coverage
  5. scaling
  6. Standardization of care in each Hospital, medical education
  7. Diagnostics & Pharma

 

Discussion Part 1
Developing Diagnostics — From Concept to the Clinic: Perspectives on the Landscape for Developing and Integrating Personalized Medicine Diagnostics into Health Systems

To kick off the “Developing Diagnostics” discussion, Moffitt Cancer Center’s DeBartolo Family Personalized Medicine Institute Medical Director Dr. Howard McLeod will moderate a conversation among leaders from the clinical, diagnostics, IT, and pharmaceutical communities about the landscape for developing and integrating personalized medicine diagnostics into health systems.
» Read More

MODERATOR | Howard McLeod, Pharm.D., Medical Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center

Assaf Halevy, Founder, CEO, 2bPrecise

  • challenge – which genetic test id relevant for which patient
  • genomic signature available to match
  • close the loop with the physician from testing, research to therapy
  • Bridge needed to assist physicians to select medications within a class: SSRI based on genomics profile

Kris Joshi, Ph.D., Executive Vice President, President, Network Solutions, Change Healthcare is the Largest IT Healthcare in the US

  • Use of Data
  • Personalized Diagnostics: Education of patients and patient taking charge because OUT OF POCKET cost till deductible is reached is very high $800 for cancer diagnostics before diagnosis is been established
  • Patients access of own medical records by 2 million patients in the US
  • Molecular diagnostics
  • Genomics data management

Peter Maag, Ph.D., CEO, CareDx

  • Transplantation patients – prolong survival of populations using markers vs negative longevity of one patient
  • Diagnostics tied to registry to demonstrate efficacy of treatment
  • 94% survival after 1 year — no one survive 5 years
  • Data sharing is long term view
  • Consortium of 27 competing organization sharing data

Hakan Sakul, Ph.D., Vice President, Head of Diagnostics, Worldwide R & D and Medical, Pfizer

  • Responsive to drug and drug efficacy is determined by diagnostics test
  • Regulatory oversight
  • consistency across countries using same drugs and same diagnostics

Kenna R. Mills Shaw, Ph.D., Executive Director, MD Anderson Institute for Personalized Cancer Therapy

  • MD Anderson Institute does not sequence genome of each patient unlike Dana Farber
  • clinicians need to access information for decision making when disease progresses – what new test to order
  • data sharing inside the institution is not complete HOW data can be shared across institution

Discussion Part 2
Developing Diagnostics — The Role of Research: A Closer Look at Efforts to Encourage the Clinical Adoption of Personalized Medicine Diagnostics by Studying the Clinical and Economic Utility of Genomic Sequencing

During the second portion of the “Developing Diagnostics” session, a health care provider, a health economist, an industry leader, and a payer representative will join moderator and Personalized Medicine Coalition Senior Vice President for Science Policy Dr. Daryl Pritchard to examine the impact of emerging research on the clinical and economic utility of genomic sequencing for patients with diseases including but not limited to cancer and suspected rare diseases.
» Read More

MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition

  • Genomic sequencing for a single test that covers many biomarkers
  • Improve treatment efficiency
  • Growing recognizion of the need to demonstrate value, evidence for Payers to pay
  • barriers for adoption of genomic sequencing

Roy J. Gandolfi, M.D., Medical Director, SelectHealth, UT is the Payer of Intermountain Healthcare, UT

  • Regional approach vs National perspective
  • medical policies requires experts for Payer to approve a treatment
  • Consumer in the health plan – they buy insurance, self insure, safety, quality care, keep premium to affort care insurance

Lincoln Nadauld, M.D., Ph.D., Chief, Precision Health, Intermountain Healthcare, UT

  • Precision Oncology Program: Need, study, analysis outcome, publish data
  • Pharmacogenetics testing will be covered for all employees
  • Neonatal, genomic sequence of all neonatal patients
  • 500,000 people to be sequenced: Genomic information of every medical chart and measure clinical and economic outcomes

Peter J. Neumann, Sc.D., Director, Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies, Tufts Medical Center

  • clinical utility
  • evidence of value: saving by diagnostics
  • cost for quality
  • cost of diagnostics
  • cost effectiveness – characterize utility
  • cost effectiveness – study
  • Value to families
  •  value of knowledge
  • externalities

Ammar Qadan, Vice President, Global Head of Market Access, Illumina

  • Illumina is partnering with providers and Payer
  • Illumina & Blue Cross Blue Shield – 150 Million are covered for genomics 2500 genomics test done
  • Under utilization – education of physician needed
  • Illumina is building evidence for Harvard Pilgrim on theirs patient data on risk pregnancies
  • Illimina is expanding  building evidence for ALL rare diseases for all Test diagnostics developers
12:55 p.m.
Seated Luncheon
2:10 p.m.
Overcoming Opioids: Considering the Potential of Personalized Medicine to Address the Opioid Crisis in the US

Emerging technologies present new opportunities to study the genetic, biological, and environmental factors that drive public health crises, with an eye toward developing personalized medicine health care strategies that can mitigate their devastating consequences.

During this session, Dr. Alissa M. Resch, Chief Scientific Officer, Coriell Institute for Medical Research, will explore the significance of Coriell’s ongoing effort to inform interventions that may help prevent opioid addiction by identifying with more precision which patients are most likely to develop dependency on this class of drugs.
» Read More

SPEAKER | Alissa M. Resch, Ph.D., Chief Scientific Officer, Coriell Institute for Medical Research

  • CORI – Camden Opioid Reseach Initiative Camden County, NJ – 3 years longitudinal study funded by State of NJ: COriell Institute, Cooper Medical School, NJ Health, Cooper University HC
  1. Prescriptions per 100 persons
  2. overdose death pwe 100,000 persons
  3. US, NJ, Camden, County, NJ
  • 2010 – increase in Prescription
  • 2013 – Synthetic Opioid
  • 2017 – Public health epidemic

THREE ARMS Opiod USE continuum: Exposure __>>> Addiction __>>> Overdose death

  1. OPTIN – Treatment to Pain chronic
  2. GOALS 0 Genomics of Opiod Addiction treatment aptients
  3. BIOBANK – biological samples from deceased aptients: who died of ipiod-related dealth : Saliva, blood, tissue – cellular function & DNA and Stem cells

A. Identify patients at risk

B. Epigenetics

C. drug-drug interaction (combination of drugs – toxicology contribuion to mortality rates

D. Can genetic information be used to study heritability of opioid use disorder

2:30 p.m.
Assessing Progress Toward the Clinical Integration of Personalized Medicine: A Landscape Analysis

Case studies and anecdotal reports suggest that leading academic medical centers and pioneering community health systems have begun to integrate personalized medicine approaches into their clinical work streams. The extent to which health care providers more generally have begun to adopt personalized medicine strategies that go beyond the ordering of genomic sequencing, however, remains unclear.

During this session, Gary Gustavsen, Partner, Managing Director, Health Advances, will share preliminary findings from a PMC-commissioned survey that examined the landscape for the clinical integration of personalized medicine in the U.S. based on a multi-factorial definition of the field. Survey respondents included a geographically diverse set of academic medical centers and community health systems.
» Read More

INTRODUCTION | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition

SPEAKER | Gary Gustavsen, Partner, Managing Director, Health Advances

  • Across community hospital systems and Academic, across geographies, across therapeutics areas, across levels of adoption

Part I: Profiling select community health systems

Part II

III

IV Testing Guidance and Data accessibility

V Utilization of Data

VI Data sharing – Inter-institutional not cross institutions

VII Funding

Interviewees were across all functions

ADOPTION ASSESSMENT of Personalized Medicine

  • Collection of genomics data
  • Physician ordering Genomics Testing
2:50 p.m.
The 15th Annual Leadership in Personalized Medicine Award

After accepting the 15th Annual Leadership in Personalized Medicine Award, Genomic Health Chief Scientific Officer Dr. Steven Shak will share his vision for the future of the field with conference attendees.
» Read More

INTRODUCTION | Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health

  • ex-Genetech: Herceptin, CF therapy
  • Genomic Health – 130 studies

AWARDEE | Steven Shak, M.D., Co-Founder, Chief Scientific Officer, Genomic Health

1986 – Joined Genetech to work on big goals and big ideas

TPA – clinical trials

CF cases – Enzyme clone DNA – tube od sputum inside enzyme – first drug to CF approved in 1997, 30 years a go gene clones

Heceptin – 90% of Breast cancer is treated by – one injected antibody on solid tumor, metastatic BR CA

2000 – Genomic Health was launched 4 out of 100 benefited from chemotherapy

  • Oncotype – can improve care and reduce cost
  • NCI Trial breast cancer 10,000 – 2018 concluded
  • Chemo therapy was transform to a targeted drug – molecular insights
  • Academia, Industry Govenment – no walls – optimally innovate
  • More precision Teamwork, Precision Leadership — NEEDED
  •  Fragmented care
  • Four request: End in mind, few target truth seeking, experiment and continue to learn, be honest with yourself,
  • evemy of innovation is illusion the answer is known
  • loose key changes
  • communitive: inspire others, challenge self and others,
  • Clinical Trials: learn from enrolees

 

3:20 p.m.
Networking Break
4:00 p.m.
Wellness in the Workplace: Understanding the Opportunities and Challenges Associated With Employer-Sponsored Genetic Testing Programs for Healthy Patients

Reasoning that genetic testing may encourage healthy lifestyles by providing information about an employee’s relative risk of developing various diseases, employers seeking to improve patients’ lives and mitigate downstream health care costs have begun to sponsor genetic testing for healthy employees by partnering with various genetic testing companies, some of which sell the tests directly to consumers.

This session, moderated by Quest Diagnostics Chief Medical Officer Dr. Jay G. Wohlgemuth, who is responsible for overseeing health care benefits for Quest’s employees, will spotlight two employer-sponsored genetic testing partnerships and explore the relevant issues. The panel discussion will focus on the significance of information generated from genetic testing, the differences between various genetic testing business models, and the privacy risks associated with the collection of genetic data.
» Read More

MODERATOR | Jay G. Wohlgemuth, M.D., Chief Medical Officer, Senior Vice President, Quest Diagnostics

  • Employers employ Pharmacogenetics, select by polypharmacy
  • Mental Health engagement through employer is problematic

Jane Cheshire Gilbert, C.P.A., Director, Retiree Health Care, Teachers’ Retirement System of Kentucky

  • average 74, 15 prescriptions on average, 65% are 84 years old
  • contain cost for retirees teachers in KY – pool of $$ for medications covered
  • 72% women 28% male
  • 36,000 retirees
  • 64% drug changes due to review following genetic testing 80% of change Medication recommended by Pharmacist was accepted by physicians

Michael Doney, M.D., Ph.D., M.S., Head of Medical Affairs, Color

  • Genetic counseling

Karen E. Knudsen, M.B.A., Ph.D., Executive Vice President, Oncology Services, Jefferson Health; Enterprise Director, Sidney Kimmel Cancer Center at Thomas Jefferson University

  • 36,000 employees all enrolled in

Scott Megill, President, CEO, Coriell Life Sciences

  • Pharmacogenomics
  • provide consultation to patient and physicians
  • Pharmacy team provide services to populations, delivery of medication plan
5:00 p.m.
Preparing Policies: A Keynote Address on the Policy Landscape for Personalized Medicine by Dr. Scott Gottlieb, Resident Fellow, American Enterprise Institute

During this keynote address, former U.S. Food and Drug Administration (FDA) commissioner Dr. Scott Gottlieb will share his thoughts on the evolving policy landscape for personalized medicine.
» Read More

INTRODUCTION | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

SPEAKER | Scott Gottlieb, M.D., Resident Fellow, American Enterprise Institute

  • create incentives in clinical trial
  • personalized care
  • improve delivery of care
  • Create a new framework for clinical trials
  • cell based therapy to get approval  advanced the frameworkCommon molecular features of a cancer enabling – common backbone change only pathways without the need to recreate the backbone again for another clinical trial
  • site licenses vs individual investigator in need for site license
  • 4 concorsium on this topic
  • innovations on data: data network for post market surveillance
  • Insights on drug safety drug efficacy – model simulation team 35 persons – adoption faster
  • standardize Drug Review: Standard Template vs collections of Drug application process
  • O&D Report tobe standardized
  • legislative solution for diagnostics – laboratory tests and lab-developed tests
  • Digital health tools – slow adoption in context of drug approval drug label put tool into promotional material
  • Taking less risk will affect negatively innovations done by policy in place: Like Gene editing and regenerative medicine vs a small molecule that the biology is well understood
  • Design Part D – premium came lower, specialty drugs, incentives to encorage NEW drugs development like alternative to statins
  • Value delivered to consumers: FDA determination for expeditious approval than coverage need to follow easier to get investment in the development process
  • CMS is setting the ceiling not the floor and its coverage is followed by the entire market size wise
  • DNA data set was EKG on AppleWatch NGS and AI Medical Devices – same approach taken
5:45 p.m.
Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

6:00 p.m.
Welcome Reception at the Isabella Stewart Gardner Museum

 

PART II

Targeting Treatment

8:00 a.m.
Registration and Breakfast

Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115

8:50 a.m.
Opening Remarks

SPEAKER | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics US

8:55 a.m.
Welcoming Remarks

SPEAKER | Joseph B. Martin, M.D., Ph.D., Dean Emeritus, Harvard Medical School

Personal story of familial heritage from Europe to Alberta, CA

9:00 a.m.
Going Global: Learning From Governmental Efforts to Advance Personalized Medicine Around the World

Global leaders are working to accelerate an era of personalized medicine around the world by encouraging innovation, modernizing policies, and reforming health systems to speed the clinical adoption of personalized medicine products and services.

During this panel discussion, four governmental representatives will share their visions for the future of personalized medicine and elaborate on their efforts to accelerate progress in the field.
» Read More

MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, EATRIS (European Infrastructure for Translational Medicine)

  • Education of the Medical community on genomics and its use in therapy
  • Japan and Denmark are building national sequencing centers

Wadha Al Muftah, M.D., Ph.D., Manager, Clinical Initiatives, Qatar Genome Program

  • 2011BioBank launched as national resource, 20,000 Quataris 3,000 foreigners recruited
  • Interest in the population to understand their Genome for future health
  • Rare disease identified
  • Training & Education in schools about the Genome using comics, Education of Healthcare professionals about Genomics
  • At the University level – Genetic counseling by professionals that understand the culture of patients
  • Precision medicine education for physicians
  • Centralized genomics implementation because the health system is centralized
  • A Pilot study on Cardiovascular Genomics

–>>>>>>>>>> Not attended —<<<<<<<<< Noella Bigirimana, Strategic Advisor, Rwanda Biomedical Center, Ministry of Health, Government of Rwanda; Government Fellow, World Economic Forum

Erja Heikkinen, Ph.D., Deputy Director, General Ministry of Education and Culture, Finland

  • Helsinki – leading cancer research academic center
  • Infrastructure investment in data management and representation of all pharma companies in Finland, all big pharma have offices in Finland
  • English is the language of communication in the research community
  • Three political parties and three ministries
  • Center for Research in Genomic is centralized and is in construction — Research will be following a distributed system of research centers in multiple locations
  • National investment in Genomics like in to other time in the past in any other discipline in Medicine

Raquel Yotti, M.D., Ph.D., General Director, Instituto de Salud Carlos III (Spain)

  • Universal coverage centralized national healthcare system
  • research is national and ministry of Health funds research and integrate it with the health system
  • interaction of clinical application and research studies
  • pharmaco-genomics, genomics testing,
  • challenge – therapies based on genetics and access to all the populations, safety and quality
  • PCPs are a source in the system, network used for systemic change and involve the clinical community including the PCP community
  • International organization under the umbrella of International Personalized medicine – the purpose of Research vs practicing Medicine
  • Government and industry manufacturing cell lines
  • Distribute results of genomics sequencing
10:00 a.m.
Networking Break
10:15 a.m.
Innovation in the Era of Personalized Medicine: A Keynote Conversation With Dr. Paul Stoffels, Chief Scientific Officer, Johnson & Johnson

During this fireside chat with CNBC Reporter Ms. Meg Tirrell, Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels will help frame the second half of the conference program by sharing the pharmaceutical industry’s perspective on the emerging issues in health care, touching on topics including costs, prices, and access.
» Read More

MODERATOR | Meg Tirrell, Reporter, CNBC

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson

Goals of medicine in 2019

  • early detection
  • Vaccines in disease prevention
  • Longevity

Challenges

  • Platforms are established, every 20-30 another one emergences
  • access to data – critical platform
  • AI for diagnostics and decision making,
  • biomarkers
  • J&J try to learn on every disease: Lungs and GI
  • Diagnosis, Medical devices,
  • Genomics testing done with diagnosis
  • HIV Vaccine – long development cycle
  • Passion of Scientists
  • pharmaceutics development is based on insights looking into the future – important goal to solve
  • Combination therapy emerges, MOA
  • partnerships: cell therapy can transform cancer treatment

 

10:45 a.m.
Prospecting the Pipeline: Exploring the Implications of a Biopharmaceutical Pipeline Dominated by Personalized Treatments

As researchers develop an enhanced understanding of the molecular causes that underpin various diseases, many biopharmaceutical companies have begun to develop therapies that are targeted to patient subgroups and even personalized to individual patients. In oncology, for example, there are reportedly more than 900 personalized “immunotherapy” treatments being tested in the clinic, with more than 1,000 in preclinical development. The challenging scientific questions and systemic implications associated with these new therapies do not always fit neatly into existing regulatory, payment, and care delivery frameworks.

During this session, CNBC Reporter Ms. Meg Tirrell will moderate a panel discussion that explores the scientific, regulatory, reimbursement, and other systemic issues associated with future gene editing treatments, gene therapies, immunotherapies, and targeted therapies. The panelists, who include industry representatives, a researcher, and an academic leader, will also consider a new approach to immunotherapy for cancer patients in which a unique product is developed for every patient treated.
» Read More

MODERATOR | Meg Tirrell, Reporter, CNBC

Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania’s Perelman School of Medicine

  • CAR-T therapy started the Transfusion Medicine & Therapeutic Biology industry
  • no relations explored between Immune T cells and microbiome
  • Cost of CAR-T therapy – use of off the shelf CAR=T cells will lower the proce while it will scale up if no rejection
  • DOGS USED WITH CAR-T TREATMENT OF CANCER IN DOG

 

Harpreet Singh, Ph.D., CEO, Immatics

  • T Cell peptide started 15 years ago Peptonomics,
  • tumors of solid cancer – cell therapies selected from libraries
  1. off the shelf cells from health donors
  2. Biologics bridges tumor cells and solid cells

Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson

  • Impact of Mirobiome it plays a key role in many diseases
  • difficult to develop therapeutics derived from microbiome data
  • Price of Drug support innovations that are transformational need to be valued by society

Alex Vadas, Ph.D., Managing Director, Partner, LEK Consulting

  • TECHNOLOGY TO SELECT COMBINATION THERAPIES

 

11:45 a.m.
Bag Lunch
12:45 p.m.
Balancing Business and Social Objectives to Advance Personalized Medicine: A Case Study of the Dementia Discovery Fund

This interactive case study discussion will explore how and why a group of government agencies, nonprofit organizations, and pharmaceutical companies came together to support the Dementia Discovery Fund, focusing on whether a disease-specific venture that seeks to create meaningful new medicines in part by capitalizing on the evolving science underpinning personalized medicine can successfully balance social and business objectives.
» Read More

MODERATOR | Richard Hamermesh, D.B.A., Co-Faculty Chair, Harvard Business School Kraft Precision Medicine Accelerator

1:45 p.m.
Toward a Shared Value Proposition in Health Care: Pursuing Value-Based Solutions in Research, Regulation, Reimbursement, and Clinical Adoption

To advance the principles of personalized medicine, the field’s proponents will need to align representatives from multiple sectors of the health system on a shared value proposition that recognizes the importance of addressing the shortcomings of one-size-fits-all medicine.

During this session, M2Gen Executive Chairman Dr. William S. Dalton will convene a commercial payer, an industry representative, a patient, and a value assessment framework developer to explore research, regulatory, clinical adoption, and especially reimbursement solutions that will, in the interest of patients, advance the principles of personalized medicine.
» Read More

MODERATOR | William S. Dalton, Ph.D., M.D., Executive Chairman, M2Gen

Bonnie J. Addario, Co-Founder, Chair, GO2 Foundation for Lung Cancer

Sarah K. Emond, Executive Vice President, Chief Operating Officer, Institute for Clinical and Economic Review

Anne-Marie Martin, Ph.D., Senior Vice President, Global Head of Precision Medicine, Novartis Pharmaceuticals Corporation

Michael Sherman, M.D., Chief Medical Officer, Senior Vice President, Harvard Pilgrim Health Care

2:45 p.m.
Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

Read Full Post »

eProceedings – Day 1: Charles River Laboratories – 3rd World Congress, Delivering Therapies to the Clinic Faster, September 23 – 24, 2019, Cambridge, MA

Posted in Conference Coverage with Social Media, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Drug Carrier Design, Drug Delivery Platform Technology, Drug Development Process, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment on July 19, 2019| Leave a Comment »

eProceedings – Day 1: Charles River Laboratories – 3rd World Congress, Delivering Therapies to the Clinic Faster, September 23 – 24, 2019, 25 Edwin H. Land Boulevard, Cambridge, MA, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

eProceedings – Day 1: Charles River Laboratories – 3rd World Congress, Delivering Therapies to the Clinic Faster, September 23 – 24, 2019, 25 Edwin H. Land Boulevard, Cambridge, MA

 

https://events.criver.com/event/9eab0ee1-982e-42c6-a4cd-fb43f9f2f1d0/confirmation:7c68cf9b-c599-469e-b602-42178c77e4f9

 

ANNOUNCEMENT

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in Real Time for pharmaceuticalintelligence.com 

Confirmation Number: 8ZNCBYNGHCK

In attendance generating in realtime event’s eProceeding and social media coverage by

 

Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

#crlworldcon

@CRiverLabs

@pharma_BI

@AVIVA1950

 

 

Join us this year as we explore novel approaches to drug development that effectively reduce program timelines and accelerate delivery to the clinic. Using a variety of case studies, our speakers will illustrate methods that successfully cut time to market and highlight how artificial intelligence and genomics are expediting target discovery and drug development. In an agenda that includes presentations, panel discussions, and short technology demonstrations, you will learn how the latest science and regulatory strategies are helping us get drugs to patients faster than ever.

AGENDA

Day One, September 23, 2019

  • Novel approaches to silence disease drivers
  • The role of AI in expediting drug discovery

Monday, September 23

8:30 – 9:00 a.m. Introduction and Welcome Remarks James C. Foster, Chairman of the Board, President, and Chief Executive Officer, Charles River
9:00 – 9:30 a.m. 2019 Award Winner: A Silicon Valley Approach to Understanding and Treating Disease Matt Wilsey, Chairman, President, and Co-Founder, Grace Science Foundation
9:30 – 10:15 a.m. Keynote Session Brian Hubbard, PhD, Chief Executive Officer, Dogma Therapeutics
10:15 – 10:30 a.m. Break
10:30 – 11:15 a.m. Novel Approaches to Silence Disease Drivers Systemic Delivery of Investigational RNAi Therapeutics: Safety Considerations and Clinical Outcomes Peter Smith, PhD, Senior Vice President, Early Development, Alnylam Pharmaceuticals
11:15 a.m. – 12:00 p.m. Novel Approaches to Silence Disease Drivers: Considerations for Viral Vector Manufacturing to Support Product Commercialization Richard Snyder, PhD, Chief Scientific Officer and Founder, Brammer Bio
12:00 – 1:00 p.m. Lunch
1:00 – 1:45 p.m. Accelerating Drug Discovery Through the Power of Microscopy Images Anne E. Carpenter, Ph.D., Institute Scientist, Sr. Director, Imaging Platform, Merkin Institute Fellow, Broad Institute of Harvard and MIT
1:45 – 2:30 p.m. The Role of AI in Expediting Drug Discovery Target Identification for Nonalcoholic Steatohepatitis Using Machine Learning: The Case for nference Tyler Wagner PhD, Head of Cardiovascular Research, nference
2:30 – 2:45 p.m. Break
2:45 – 3:30 p.m. Technobite Sessions with Emulate Bio and University of Pittsburgh Drug Discovery Institute

Kyung Jin H Jang, VP of Bio Product development, Emulate, Inc.

Albert Gough, PhD, U Pittsburg School of Medicine
3:30 – 4:15 p.m. Artificial Intelligence Panel Discussion: Real World Applications from Discovery to Clinic Moderated by Carey Goldberg, WBUR
4:15 – 4:45 p.m. Jack’s Journey Jake and Elizabeth Burke, Cure NF with Jack
4:45 – 5:00 p.m. Closing Remarks
5:00 – 6:00 p.m. Networking Reception

 

 

Day Two – September 24, 2019

  • How genomics is expediting drug discovery
  • Accelerating therapies through the regulatory process

Tuesday, September 24

8:45 – 9:00 a.m. Opening Remarks and Recap James C. Foster, Chairman of the Board, President, and Chief Executive Officer, Charles River
9:00 – 9:30 a.m. 2018 Award Winner Update David Hysong, Patient Founder and Chief Executive Officer, Shepherd Therapeutics William Siders, CDO, Shepherd Therapeutics
9:30 – 10:15 a.m. Advances in Human Genetics and Therapeutic Modalities Enable Novel Therapies Eric Green, Vice President of Research and Development, Maze Therapeutics
10:15 – 11:00 a.m. How Genomics is Expediting Drug Discovery Manuel Rivas, Assistant Professor, Department of Biomedical Data Science, Stanford University
11:00 – 11:15 a.m. Break
11:15 a.m. – 12:00 p.m. Genomics Panel Discussion: Signposting Targets That Will Speed the Path to Market Moderated by Martin Mackay, Co-Founder, RallyBio
12:00 – 1:00 p.m. Lunch
1:00 – 1:45 p.m Truly Personalized Medicines for Ultra-rare Diseases: New Opportunities in Genomic Medicine Timothy Yu, Attending Physician, Division of Genetics and Genomics and Assistant Professor in Pediatrics, Boston Children’s Hospital
1:45 – 2:30 p.m. Application of Machine Learning Technology for the Assessment of Bulbar Symptoms in ALS Fernando Vieira, Chief Scientific Officer, ALS Therapy Development Institute
2:30 – 2:45 p.m. Break
2:45 – 3:30 p.m. Accelerating Rare Disease Therapies Through the Regulatory Process Martine Zimmermann, Senior Vice President and Head of Global Regulatory Affairs, Alexion Pharmaceuticals, Inc.
3:30 – 4:00 p.m. Wearing ALL the Hats: From Impossible to Possible Allyson Berent, Chief Operating Officer, GeneTx Biotherapeutics
4:00 – 4:15 p.m. Closing Remarks

 

jim.jpg
Matt_Wilsey.jpg
  • Find a cause and work with passion
  • CVD increased 53% from 2005 to 2016
  • Cholesterol, LDL receptor and CV disease
  • Genetics  evolution and discovery of PCSK9
  1. A PCSK9 Variant lowers CV risk
  2. complete lack of PCSK9 is safe – protects from CVD
  • LDL receptor
  • Statins do not work on LDL receptor if the mutation exists
  • Antibody and antisense for the PCSK9 mutation – Inexpensive Oral Medications can change Global Diseases
  • Dogma of Drug DIscovery: Approach a Patent vs Approach a Disease
  • Ligands bind within a cryptic binding pocket adjacent to a novel PCSK9 polymorphism

12 years of drug discovery

  1. 2003: PCSK9 mutation discovered
  2. 2005:
  3. 2006:
  4. 2012;
  5. 2012: Dogma Scientists begin
  6. compound found binds to primates
  7. 2015:
  8. 2018: Efficiency DGM-4403 lowers LDL-c by 55% 0ver 14 days
peter smith.jpg
  • 2014 – @Moderna, mRNA
  • 2017 – Alnylam

RNAi – delivery is the most difficult

  • gene silencing changes medicine and diseases
  • Small Interfeering RNA (siRNA) Therapeutics
  • Delivery challenges – stability and targeting
  • RNA Interference (RNAi) – Onpattro (patisiran)
  • GalNAc-siRNA Conjugates – delivery to the hepatocytes
  • N-Acetyl Galactosamine (GalNACc-siRNA conjugates
  • Hepatocyte specific : Liver across species: ASGPR expression
  • Metabolic Stability: Chemistry to Improve siRNA
  • Platform for genetic diseases
  • Evolution of COnjugate Design: GalNAc-siRNA – enhanced stabilization chemistry
  • ALN-TTRSC02 compared to Revusiran
  • ALN-TTRsc02 (advanced) –  – tetrameric protein binds transports serum retinol binding
  • AL Amyloidosis
  • ApoA1 Amyloidosis
  • ATTR Amyloidosis – manufacture in the Liver: Hereditery vs non-hereditary – Wild-Type
  • Patisiran Therapeutic Hypothesis – siRNA targeting TTR formulated
  • Pharmacology of TTR siRNA in Animal Model
  • V30M TTR Transgenic Mouse Model: Patisiran Phase 1 Study to Phase 3 APOLLA Study Design for any TTR mutation – Prior tetramer stabilizer used permitted
  • hATTR Amyloidosis and APOLLO Assessment: Phase 3 is Global – Cardiomyopathy – potential,
  • Patisiran met all secondary Endpoints: Canadian, Japanese approval – US approved indication, European approved
  • Alnylam Investigational RNAi Therapeutics:
  • Pipeline: Genetic medicines
  • Hepatic Infectious diseases
  • CNS & Ocular
  • Cardiovascular
11:15 AM-12:00 PM
richard snyder.jpg
  • Viral-Vector-mediated in vivo Gene Therapy
  • VVS Viral Vector Platforms:
  1. Adenovirus immunogenicity
  2. Lentivirus
  3. Retrovirus
  4. Herpes
  5. Recombinant Adeno-Associated Viral Vectors: Glybera, Luxturna
  6. Zolgenzma
  • Establish the product specifications based on data (CQAs)
  • Is the vector product: parenteral or anciliary material

Considerations:

  • Large scall vs small
  • lot demand vs platform choice
  • Proof of concept
  • Own/License the manufacturing reagents (portability) vs reliance on providers
  • Process and Analytical Design & Development: Cell line: Mamalian, others
  • Raw materials: Viral clearance steps – cell banks generation
  • impurity profiles
  • Cell Substrates
  • Cell clone screening
  • Preclinical/Clinical, Alachua, FL; Phase III/Commercial: Cambridge & Lexington
  • Biologics Upstream Process Flow: Master cell banks
  • Transient Transfection Process (Lenti and AAV)
  • rAAV Proviral cell line
  • Production Vector-based Process (Baculo or HSV)
  • Product purification: Filtration methods, Chromatography, centrifugal separation: Concentration/filtration
  • Formulation
  • Compatibility wiht vial: Glass, CZ, COP: absorption vs Inactivation
  • Single use
  • Frozen storage
  • Storage, Packing and Distribution
  • Technology Transfer: Research vs Mature Process (Qualified cell bank)
  • Plasmids: E.coli MCB backbone
  • Analytics Design & Development: Testing: Nucleic-acid based, protein-based
  1. AAV Vector Lot Release Assays
  2. Lentivirus
  • QA: QA Management System –
  • Analytical Assays
  • FDA Issues SIX New Draft Guidance Documents in 7/2018
  • Process Validation: Life cycle approach: Process caracterizationProcess performance qualification
Anne_Carpenter photo (003).jpg
  • assayGene clusterbased on morphological similarity: Express each gene, gene painting Image analysis, cluster morphological profiles
  • identification of allelle that are not constitutively activating mutants.
  • weakly supervised deep learning to extract features
  • identify similarities and differences among treatments at the same population level
  • Predict many distinct expensive assays on a huge compound library using a single cell painting
  1. Test 5,000 compounds in the assay of interest as well as cell painting
  2. Find combination of iamge-based features that predict in the assay of interest
  3. Predict “hit” from existing 1Million compound cell paining data set
The Role of AI in Expediting Drug Discovery Target Identification for Nonalcoholic Steatohepatitis Using Machine Learning: The Case for nference
Tyler Wagner PhD, Head of Cardiovascular Research, nference
KJ.jpg
DT.jpg
  • Lung-Chip Applications
  • Pulmonary inflammation
  • Intestine-chip Applications
  • Liver-Chip: Building Tissue Complexity: Co-culture, tri-culture, quatro-culture, Transcriptomic Analysis
  • Liver-Chip: Kupffer cells Characterization
  • Stellate Cells
  • parenchymal channel, non-parenchymal channel
  • Liver Chip: Predicting species differences in liver toxicity: Effects of Bosentan on Albumin secretion
  • Acetaminophen Toxicity in Liver-Chip: APAP Metabolism: detected changes in morphology, ATP, GSH – Dosepdependent increase of ROS
  • Steatosis and Stellate Cell Activation: and Species difference in Toxicity Liver chip data correlates with in vivo data
  • Predict Human safety risks with liver chip
Albert Gough, PhD, U Pittsburg School of Medicine
  • Approaches for repurposing drugs:
  1. Integrated, fluidic organ MPD,
  2. cells, 3D structures,
  3. O2 Modulation & Sensing
  4. Biosensors
  5. secretome
  • Higher Biomimetic content Higher throughput
  • regulatory liver-pancreas axis in Type 2 Diabetes model
  • Estradiol-Induced proliferation of mutants in Breast Cancer varies from 2D monoculture to 3D LAMP
  • MPS Models:
  1. celle and organ Structure in MPS
  2. Single organ MPS & Coupled organ
Carey Goldberg.PNG
Carey Goldberg, WBUR
burke family.jpg

September 24, 2019

jim.jpg
david hysong.png
bill siders.png
eric green.jpg
MacArthurD.jpg
mackay_1644931c.jpg
timothy yu.jpg
fernando-vieira.jpg
crop-VOISCHTS-Presenter-ZimmermannM.png
Allyson-Berent.jpg

Read Full Post »

« Newer Posts - Older Posts »